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Abstract 
JACLYN WILLETTE ELLIS: The Multi-Ethnic Investigation of Gene and Gene-
Environment Interactions for Biochemical Markers associated with  
Cardiovascular Disease 
(Under the direction of Leslie Ann Lange) 
 
 
Cardiovascular disease (CVD) is the leading cause of illness and death worldwide 
with an estimated annual one million deaths occurring in the United States alone.  
Biomarkers of systemic inflammation, such as C-reactive protein (CRP), and metabolism, 
such as homocysteine, have been shown to be predictive of clinical CVD.  CRP, an acute 
phase inflammatory protein, has been shown to have a moderate degree of heritability 
with estimates ranging between 25% and 40%.  Previous reports have identified 
approximately twenty genetic loci to be associated with CRP.  Homocysteine is a sulfur-
containing nonessential amino acid derived from methionine and recently, evidence has 
elucidated a relationship between this amino acid and inflammation.  Similar to CRP, 
elevated levels of homocysteine have been linked to cardiovascular complications, and 
heritability estimates are in the range of 47% to 70%.  Further, while it has been well-
demonstrated that environmental influences such as cigarette smoking significantly 
contribute to the development of CVD, it is less clear how genetic variants modify the 
effects of these risk factors on cardiovascular biomarkers.  There are few studies that 
have assessed gene-environment interaction effects on CVD-related biomarkers.  Finally, 
most genetic studies of CVD-related biomarkers have focused on populations of non-
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European ancestry. Therefore, we assessed how common and less common gene variants 
influence CRP and homocysteine levels in a multi-ethnic setting, and investigated 
whether genetic variants in two glutathione-S-transferase genes, which play a 
detoxification role, modify the association between cigarette smoking and CRP level.  
We used African-American (AA), European-American (EA), and European (EU) 
participants from several cohort studies from the Candidate gene and Association 
Resource (CARe), the Women’s Health Initiative (WHI), and Cooperative Health 
Research in the Region Augsburg (KORA) studies. 
 We identified novel genetic risk factors for CRP and homocysteine levels as well 
as evidence for the interplay between genes and environment on CRP.  Overall, our 
results provide important insight regarding the pathophysiology of CVD and 
atherosclerosis as well as place emphasis on the need to conduct more genome-wide and 
candidate gene association studies in non-European populations.  
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CHAPTER 1 
                                      INTRODUCTION 
 
CVD, primarily heart disease and stroke, is the leading killer in the US for both 
men and women among all racial and ethnic groups.  The most recent statistics on 
mortality rates show that CVD accounts for approximately 33% of deaths in the US 
(Roger et al., 2011). Each year an estimated 785,000 Americans will have a new coronary 
attack and an additional 195,000 will experience a silent myocardial infarction (MI) 
(Roger et al., 2011).  Furthermore, mortality rates are much higher in minority 
populations with the highest being in African Americans (AA) (Roger et al., 2011).  A 
recent statistical report by the American Heart Association (AHA) stated that overall 
death due to CVD is greater for AA males and females than their European-American 
(EA) counterparts (Roger et al., 2011).  In 2008, the rates per 100,000 individuals were 
the following: 287.2 for EA males, 390.4 for AA males, 200.5 for EA females, and 277.4 
for AA females (Roger et al., 2011).  
Inflammation is a complex defense mechanism in which leukocytes migrate from 
the vasculature to damaged tissues to inhibit agents that could cause tissue injury(Gabay, 
2006). Research from clinical and population studies suggest that inflammation is an 
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important factor in the development of atherosclerosis and the triggering of MIs and 
strokes (Roger et al., 2011).  Persistent inflammation may contribute to plaque instability, 
disruption, and ultimately thrombosis leading to a cardiac event (Gabay, 2006; Roger et 
al., 2011). Thus, measuring the inflammatory activity in the plasma of individuals may 
provide an alternative method of CVD risk prediction(Libby, Ridker, & Maseri, 2002).   
The study of biomarkers can provide a better understanding of CVD development 
and progression.  Because they can be assessed before a clinical event occurs, biomarker 
can be used to identify individuals at increased risk of experiencing a CVD event, which 
can facilitate targeted interventions.  Because biomarkers are more proximal to a gene 
product than and offer less complexity than a CVD endpoint, the use of biomarkers as 
outcomes in studies may increase statistical power to detect associations (Brattstrom, 
Lindgren, Israelsson, Andersson, & Hultberg, 1994; Sing, Stengard, & Kardia, 2003).   
Over the past decade, several biomarkers of inflammation have been linked to 
incident vascular events; however the most consistent results have been seen with C-
reactive protein (CRP) (Conen & Ridker, 2007).  CRP is a biomarker of systemic 
inflammation released by the cytokine interleukin 6 (IL-6) and plays an active role in the 
innate immune response (Ansar & Ghosh, 2013).  Epidemiological studies have observed 
elevated levels of CRP in patients with hypertension and metabolic syndrome, which are 
both CVD risk factors.  Homocysteine is a biomarker metabolically linked to lipid 
metabolism through the methionine cycle (Williams & Schalinske, 2010).  Studies using 
animal models and human subjects have demonstrated that elevated levels of 
homocysteine induce endothelial dysfunction, which refers to the impairment of normal 
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homeostatic properties including inflammation (Cai & Harrison, 2000).  Consequently, 
increased homocysteine levels have been associated with increased CVD risk.    
This dissertation consists of three chapters that aim to assess the genetic 
influences of both CRP and homocysteine in a multi-ethnic cohort setting with a specific 
focus on African Americans.  The first two chapters are aimed at using the IBC panel to 
identify genetic variants associated with CRP and to assess whether variants in two 
glutathione-S-transferase genes modify the effects of cigarette smoking exposure on 
CRP.  The third chapter is aimed at performing a genome-wide association scan to 
identify loci that influence homocysteine levels in African Americans. 
Cardiovascular Disease and Atherosclerosis 
 
Cardiovascular disease (CVD) is a class of diseases that affect the cardiovascular system, 
primarily cardiac diseases, vascular diseases of the brain, and peripheral arterial diseases. 
CVD results in the interaction of multiple genes and environmental factors (Lusis, 
Fogelman, & Fonarow, 2004; Lusis, Mar, & Pajukanta, 2004; Q. Wang, 2005).  Clot 
formation and atherosclerosis remain the hallmarks in the pathology of CVD (Prandoni et 
al., 2003).  Despite pharmacological approaches to lower cholesterol levels, CVD 
continues to be the principal cause of death in the US, Europe, and much of Asia 
(Braunwald, 1997; Breslow, 1997). 
Inflammation plays a critical role in the pathogenesis of atherosclerosis.  The 
process of atherogenesis has been considered to consist largely of the accumulation of 
lipids within the arterial wall (Ross & Glomset, 1976a). Atherosclerotic lesions result 
from a highly specific cellular and molecular response with a major inflammatory  
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component.  The lesions occur primarily in large and medium-sized elastic and muscular 
arteries that can lead to ischemia of the heart, brain, or extremities, and eventually 
resulting in infarction.  The lesions can be present throughout a person’s lifetime and the 
earliest type of lesion, called the fatty-streak (consisting of monocyte-derived 
macrophages and T lymphocytes), can be found in individuals as early as infancy (Napoli 
et al., 1997).  
Endothelial dysfunction may be caused by elevated and modified low density 
lipoprotein (LDL) cholesterol, and free radicals caused by cigarette smoke, hypertension, 
diabetes mellitus, genetic alterations, or elevated plasma homocysteine concentrations 
(Ross & Glomset, 1973, 1976b).  The result from injury to the endothelium leads to 
compensatory responses that alter the normal homeostatic properties of the vasculature.  
The different forms of injury can cause an increase in the adhesion of leukocytes or 
platelets, or induce procoagulant properties to form vasoactive molecules, cytokines, and 
growth factors.  If the inflammatory response does not properly clear these agents, it can 
continue indefinitely; thereby, stimulating migration and proliferation of smooth muscle 
cells that become intermixed with the area of inflammation to form intermediate lesions 
(Jonasson, Holm, Skalli, Bondjers, & Hansson, 1986; van der Wal, Das, Bentz van de 
Berg, van der Loos, & Becker, 1989).  The characteristics of an atherosclerotic lesion 
represent a stage of chronic inflammation.  Moderate inflammation causes more 
macrophages and lymphocytes that migrate from the blood and multiply within the 
lesion.  Activation of these cells leads to the release of cytokines, chemokines, and 
growth factors, which can induce further damage and lead to necrosis, or cell death (Falk, 
1996).  Continued accumulation of macrophages can lead to the enlargement and 
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restructuring of the lesion so that it becomes covered by a fibrous cap.  Eventually, the 
artery will no longer be able to compensate by dilation and this advanced lesion can then 
intrude into the lumen and alter blood flow (Ross, 1999). 
LDL cholesterol is a major contributor to injury of the endothelium and this 
process can be modified by oxidation, glycation, aggregation, or incorporation of the 
immune complex (Khoo, Miller, McLoughlin, & Steinberg, 1988; Khoo, Miller, Pio, 
Steinberg, & Witztum, 1992; Navab et al., 1996; Steinberg, 1997).  When LDL particles 
become trapped in an artery, they can undergo oxidation and be internalized by 
macrophages via scavenger receptors on the surface of endothelial cells (Griendling & 
Alexander, 1997; Khoo et al., 1992; Morel, Hessler, & Chisolm, 1983; Navab et al., 
1996).  The internalization leads to the formation of lipid peroxidases and facilitates the 
accumulation of cholesterol esters, which result in the formation of foam cells.  The 
degree to which LDL is modified can vary greatly (Diaz, Frei, Vita, & Keaney, 1997; 
Griendling & Alexander, 1997; Han, Hajjar, Febbraio, & Nicholson, 1997), which is why 
the removal and sequestration of modified LDL are important parts of the initial 
protective role of macrophages in the inflammation response (Diaz et al., 1997; Falcone, 
McCaffrey, & Vergilio, 1991; Han et al., 1997).  The inflammatory response itself can 
have a profound effect on lipoprotein movement within the artery.  Specifically, 
mediators of inflammation such as tumor necrosis factor α (TNFα) and interleukin-1 (IL-
1) increase the binding of LDL to the endothelium and smooth muscle, and increase 
transcription of the LDL-receptor gene (LDLR).  Smooth muscle cells in the media of 
arteries, as well as lesions, are surrounded by different types of connective tissue.  In the 
media of arteries, the matrix consists largely of type I and III fibrillar collagen, whereas 
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lesions of atherosclerosis contain proteoglycan intermixed with loosely scattered collagen 
fibrils.  Collagen inhibits cell proliferation by up-regulating specific inhibitors of the cell 
cycle (Koyama, Raines, Bornfeldt, Roberts, & Ross, 1996).  Degradation of the collagen 
or its migration away from inhibitors may cause smooth muscle cells to replicate.  The 
degradation and migration of other matrix molecules that can also inhibit the cell cycle 
may lead to the expression of chemokines by macrophages (Assoian & Marcantonio, 
1996; Mercurius & Morla, 1998; Wesley, Meng, Godin, & Galis, 1998).  Thus, the 
matrix surrounding smooth muscle cells greatly influence the fate of these cells (Wesley 
et al., 1998). 
Monocyte, the precursor of macrophages in all tissues, is present at every phase of 
atherogeneis.  Monocyte-derived macrophages are scavenging and antigen-presenting 
cells that secrete cytokines, chemokines, growth-regulating molecules, and other 
hydrolytic enzymes.  Inflammatory cytokines can activate macrophages making them 
susceptible to apoptosis. If apoptosis occurs within the arteries, macrophages may 
become involved in necrotic cores which are characteristic of advanced atherosclerotic 
lesions (Ross, 1986).  
 Platelet adhesion and thrombosis are also abundant in the initiation and 
generation of atherosclerosis in humans and animals (Ross, 1993).  Platelets can adhere 
to dysfunctional endothelium, exposed collagen, and macrophages. These platelets can 
accumulate on the walls of arteries and recruit additional platelets into a developing 
thrombus.  Plaque rupture and thrombosis are prominent complications of advanced 
lesions that can result in coronary syndromes or myocardial infarction (Davies, 1990; 
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Falk, 1996; Ross, 1993).  Moreover, plaque rupture and thrombosis may be responsible 
for as many as 50% of cases of acute coronary syndrome and MI (Falk, 1996). 
Biochemical markers  
 
A substantial proportion of cardiovascular events occur in individuals who exhibit none 
of the classical risk factors, such as age, gender, smoking, and obesity(Hackam & Anand, 
2003).  This critical observation has led to a collective interest in identifying biomarkers 
that might improve the global risk prediction of CVD (Badimon & Vilahur, 2012).  
Biomarkers can serve as predictors of both therapeutic and adverse clinical effects.  In 
adverse clinical situations, when a patient is presented with severe chest pains, 
biomarkers of CVD can be used to differentiate whether the individual is suffering from 
an acute myocardial infarction or unstable angina (Vasan, 2006).  In clinical trials, these 
same biomarkers can also be measured to determine the efficacy of the drug being tested 
(Vasan, 2006).  Most importantly, biomarkers have also accelerated the understanding of 
CVD pathology (Medford, Dagi, Rosenson, & Offermann, 2013).  The extensive study of 
cholesterols has revealed their role as key contributors to the initiation and progression of 
atherosclerosis.  Epidemiological and clinical studies of LDL-C and HDL-C have 
elucidated its role in the mechanisms underlying the development atherosclerotic plaque.  
Exposure to elevated LDL-C levels in the endothelium decrease nitric oxide (NO) 
availability, which can lead to platelet aggregation, dysregulation of vascular tone, and 
smooth muscle cell proliferation.  In contrast, elevated levels of HDL-C can protect the 
endothelium from such occurrences (Badimon & Vilahur, 2012). 
There are multiple mechanisms underlying a complex interplay between cellular  
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components and inflammatory oxidative factors that contribute to the development of 
CVD.  In addition to LDL-C, several other blood biomarkers have been established as 
contributing to the development of atherosclerotic plaque, such as elevated levels of 
homocysteine, CRP and fibrinogen (P.M. Ridker, Rifai, Rose, Buring, & Cook, 2002).  
Measuring these makers in the plasma of individuals may provide a greater understanding 
of CVD development and progression.   Because biomarkers are more proximal to the 
gene product, the use of these as surrogate endpoints may increase statistical power to 
detect association(Ray, Le, Riou, & Houle, 2010).   
C-reactive protein 
 
CRP is a pentameric acute phase protein found in the blood in response to inflammation.  
The CRP molecule is composed of five identical non-glycosolated polypeptide subunits 
each containing 206 amino acid residues.  The promoters are non-covalently associated in 
an angular configuration giving the molecule its pentameric structure (Pietila, 
Harmoinen, Jokiniitty, & Pasternack, 1996).  The protein is mostly regulated by the 
cytokine interleukin-6 (IL-6), synthesized primarily by liver hepatocytes, and secreted in 
plasma (Morley & Kushner, 1982).  Because of its ability to recognize pathogens by 
binding to phosphocholine (PC) resulting in the activation of the complement system, 
CRP presents itself as an important constituent of innate immunity (Volanakis, 2001).  
The innate immune system discriminates self (attack of foreign molecules) from nonself 
(attack of its own immunity) using a restricted number of pattern recognition receptors 
(PRR) that recognize pathogen associated molecular patterns (McLaughlin et al., 2002).  
A study of the evolution of the human immune system reveals the development of  
 9 
 
sophisticated defense mechanisms highly specific for the invasion of pathogens 
(Garlanda, Bottazzi, Bastone, & Mantovani, 2005).  The evolutionary conservation of 
mammalian CRP sequence and specificity binding over a diverse range of species (birds, 
amphibians, marine teleosts, and sweet water fishes) suggests that it has an important 
biological role.  In fact, CRP is one of the first proteins to be described as a systemic 
biomarker for inflammation making it an important clinical biomarker (Garlanda et al., 
2005).  It was initially reported that only the liver can produce CRP; however, recent 
studies suggest that CRP may also be produced by smooth muscle cells and macrophages, 
found within atherosclerotic lesions linking it to CVD (Pepys & Hirschfield, 2003).  
There is also evidence that CRP can directly bind modified LDL cholesterol and activate 
the complement system, induce adhesion molecule expression, promote monocyte 
activation, and induce endothelial activation (Libby et al., 2002).   
Circulating plasma CRP in the blood is considered normal when levels are lower 
than 10mg/L (Clyne & Olshaker, 1999; Das et al., 2003).  In response to infection or 
tissue injury, CRP is reported to display marked increases in serum concentration 
(Morley & Kushner, 1982).  For severe bacterial infections and burns, levels tend to be 
>200 mg/L and, for viral infection tend to be in the range of 10-40 mg/L.  In response to 
trauma necrosis of tissue, aging, and most forms of inflammation, levels can increase 
about 1,000-fold 48 hours after an acute event (Clyne & Olshaker, 1999).  Research has 
focused on the use of high-sensitivity assays to measure CRP, which allow for precision 
in the very low ranges to detect increased CVD risk.  CRP level categories of < 1mg/L, 1-
3 mg/L, and >3 mg/L are used to denote low, intermediate and high risk vascular groups, 
respectively (Yeh & Willerson, 2003).  Thus, the quantitative estimation of CRP level in 
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serum is in relatively widespread use as a clinical risk predictor of CVD (Haverkate, 
Thompson, Pyke, Gallimore, & Pepys, 1997; Thompson, Kienast, Pyke, Haverkate, & 
van de Loo, 1995). 
Over 20 cohort studies have demonstrated that CRP is an independent predictor of 
major cardiovascular events. Some studies showed that CRP was the strongest risk 
determinant other than age and other studies showed its magnitude of effect to be almost 
as great as that of blood pressure, and dyslipidemia (P.M. Ridker et al., 2002).  The 
Women’s Health Study reported that elevated CRP levels were associated with the 
highest rate of vascular events and FHS demonstrated that CRP enhanced CVD risk 
prediction. The Reynolds risk score is a measure used to predict an individual’s risk of 
having a major cardiac event (P.M. Ridker, Buring, Rifai, & Cook, 2007). After adding 
information on family history of premature MI (event before age 60) and CRP to the 
Reynolds risk score calculation, some individuals who were initially considered to be at 
10-20% disease risk were reclassified at 40-50% risk. In contrast, there is also a great 
deal of controversy surrounding the use of CRP as clinical biomarker.  Since CRP is 
elevated in inflammation, the presence of any infection can limit its utility as a reliable 
predictor of CVD risk (Koenig, Lowel, Baumert, & Meisinger, 2004; P.M. Ridker et al., 
2007).  Thus, high sensitivity assays have been developed to accurately detect low 
concentrations of CRP to predict a healthy individual’s risk of CVD (Koenig et al., 
1999),. 
Despite highly consistent findings demonstrating an association between CRP and 
CVD, it is not yet clear whether there is any direct causal role of CRP in CVD  
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development. Investigators of the Reykjavik Study, which included approximately 19,000 
Icelandic elderly men and women, demonstrated that while the predictive value of hsCRP 
was statistically significant (p<0.0001), the magnitude of this effect was modest (OR<1) 
(Danesh et al., 2004a).  The Framingham Heart Study using approximately 4500 
European American men and women reported only moderate risk association between 
CRP and coronary heart disease (p~0.09) (Wilson et al., 2005) without the use of the 
Reynolds risk score.  In contrast, a study using approximately 5200 elderly men and 
women (≥ 65 years) participants from the Cardiovascular Health Study (CHS) 
demonstrated that CRP was an independent risk factor for ischemic stroke after ten years 
of follow-up where preexisting stroke was not present in the population (P<0.05) (Cao et 
al., 2003).  Another study performed by CHS using African Americans (AA) and 
European American (EA) participants identified an association with CRP SNPs and CVD 
mortality in EAs (P=0.004) and myocardial infarction in AAs (P=0.005) (Lange et al., 
2006).  Even after adjustment for plasma CRP levels, which is likely influenced by CRP 
genotype, associations were only modestly attenuated but still remained significant (P< 
0.05) (Lange et al., 2006). 
CRP levels have been shown to vary across ethnic populations. Studies have 
reported AAs to have higher CRP levels than their white counterparts and women to have 
higher CRP levels than men with the highest levels observed in AA women (Khera et al., 
2005).  A study that examined the relationship between ethnic background and levels of 
inflammation showed that AAs had higher levels of CRP and IL6 than EAs; however, 
when adjusting for socioeconomic and health variables, the differences were attenuated 
for CRP but levels of IL-6 still remained higher in AAs.  The elevated levels of IL-6 
 12 
 
observed in AAs may in part explain the increased disease risk in this population and 
furthermore may account for the health disparities between these ethnic groups (Paalani, 
Lee, Haddad, & Tonstad, 2011). 
Observational studies have shown CRP levels to be affected by factors such as 
age (Koenig et al., 1999), sex (Slade, Offenbacher, Beck, Heiss, & Pankow, 2000), 
smoking (Harris et al., 1999), diabetes, and atherosclerotic CVD (Mendall, Patel, Ballam, 
Strachan, & Northfield, 1996; R.P. Tracy et al., 1997); however, recurring evidence 
shows that CRP levels are also affected by genetic factors.  Notably, the heritability of 
CRP levels is estimated to be 25% to 40% also suggesting that genetic variation is 
another major determinant of CRP levels (Austin et al., 2004; Dehghan et al., 2011; Fox 
et al., 2008; Greenfield et al., 2004; Xu & Whitmer, 2006).  GWA studies have identified 
genetic loci to be associated with CRP.  The Women’s Genome Health Study (WGHS) 
observed six loci known to associate with CRP, which include the leptin-receptor gene 
(LEPR), CRP gene, interleukin-receptor gene (IL6R), glucokinase regulatory protein 
(GCKR), hepatic transcription factor gene (HNF1A), and the apolipoprotein-E (APOE) 
(P.M. Ridker et al., 2008).  A recent meta-analysis of approximately 80,000 participants 
of European ancestry from the Cohorts for Heart and Aging Research in Genetic 
Epidemiology (CHARGE) consortium confirmed the association of these previously 
identified loci and observed significant evidence for 11 novel genes, including NLRP3, 
HNF4A, RORA, IRF1, and IL1F10 (Dehghan et al., 2011).  A recent GWA study of 837 
individuals of African ancestry reported genome-wide significant (P<5x10
-8
) associations 
for several variants in the CRP gene and nominal (P<0.05) associations for LEPR, IL6R, 
GCKR, HNF1A, and APOE (Doumatey et al., 2012), suggesting that these loci influence 
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CRP level across populations. Specific CRP variants associated with CRP, however, have 
differed between AAs and EAs. The most associated SNP in several AA studies has been 
rs3093058, which is only polymorphic in individuals of African descent (Carlson et al., 
2005; Crawford et al., 2006), while the most associated SNP is EAs is commonly 
rs3091244 (Danenberg et al., 2003; Dehghan et al., 2011; Edberg et al., 2008). 
Homocysteine 
 
Homocysteine (Hcy) is an amino acid generated metabolically by the S-
adenosylmethionine (SAM)-dependent transmethylation pathway (Williams & 
Schalinske, 2010).  These reactions occur in most tissue cells; however the liver is the 
primary site for transmethylation and ensuing production of Hcy (Williams & Schalinske, 
2010).  The initial step for the metabolic production of Hcy is the activation of 
methionine to SAM by adenosine triphosphate (ATP)-dependent action of methionine 
adenosyltransferases.  The outcome of all SAM-dependent transmethylation is the 
generation of S-adenosylhomocysteine (SAH), which is then hydrolyzed to adenosine 
and Hcy by SAH hydrolase (I. K. Kim, Zhang, Chiang, & Cantoni, 1983).  Once Hcy has 
been produced, it can undergo two possible metabolic fates: remethylation back to 
methionine or irreversible catabolism by the transsulfuration pathway(Z. Li & Vance, 
2008).  Two tissue-specific Hcy remethylation pathways are known to exist:  1) a folate-
dependent reaction that utilizes 5-methyltetrahydrofolate as a substrate and the action of 
the B12-dependent enzyme, methionine synthase (MS); and 2)  a folate-independent route 
catalyzed by betaine-Hcy S-methyltransferase (BHMT) where betaine, an oxidation 
product of choline, serves as the methyl donor (McKeever, Weir, Molloy, & Scott, 1991).   
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For both reactions, methionine serves as an acceptor of methyl groups for the 
maintenance of essential SAM-dependent transmethylation reactions (McKeever et al., 
1991).  Transsulfuration is an alternative yet essential route in the catabolism of Hcy that 
is initiated by the action of cystathionine β-syntase (CBS), a B6-dependent enzyme to 
form cystathionine via the condensation of Hcy and serine.  Cystathionine is further 
metabolized by ƴ-cystathionine to cysteine, an essential amino acid in protein synthesis 
and the synthesis of glutathione (Mudd & Poole, 1975).  Consequently, Hcy balance is 
dependent on numerous reactions that result in its production; therefore, any potential 
disturbers of this balance could result in serious complications (Williams & Schalinske, 
2010). 
 For folate dependent remethylation of Hcy by the B12-dependent enzyme MS, 
most literature has focused on the polymorphic expression of the enzyme 5,10-
methylenetetrahydrofolate reductase (MTHFR).  For humans, a reduction in the 
enzymatic activity of MTHFR has been associated with hyperhomocysteinemia and 
vascular complications in humans (Frosst et al., 1995; Jacques et al., 1996; Nelen et al., 
1998).  For all cases of reduced MTHFR function, the hyperhomocysteinemia phenotype 
can be attributed to the compromised ability of the folate/B12- dependent pathway to 
adequately remethylate Hcy (Beagle et al., 2005; Caudill et al., 2009; Vaughn et al., 
2004).  For folate-independent Hcy remethylation using betaine as a methyl donor, 
BHMT has been shown to be a key regulator of Hcy homeostasis.  Although to date, a 
knock out mouse model has not been developed to understand the relationship between 
BHMT expression and Hcy, a pharmacological inhibitor of BHMT (S-(-carboxybutyl-DL-
Hcy)) caused an increase in total plasma Hcy levels by sevenfold (Collinsova, Strakova, 
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Jiracek, & Garrow, 2006).  For the irreversible catabolism of Hcy, previous literature has 
focused primarily on CBS, the B6-dependent enzyme.  In humans, it was observed that a 
lack of CBS expression was linked to homocystinuria, characterized by an increased 
excretion of Hcy in the urine (Mudd, Finkelstein, Irreverre, & Laster, 1965).  Using a 
mouse model, Wang, et al. demonstrated that the induction of hepatic and renal CBS 
lowered serum Hcy concentrations (L. Wang et al., 2004).  Hyperhomocysteinemia has 
been linked to many disease states in both mice and humans; however, the leading 
emphasis has been its recognition as an independent risk factor for cardiovascular 
disease. 
 Evidence has demonstrated that Hcy has atherogenic and prothrombotic 
properties. There are multiple mechanisms on how Hcy may induce vascular injury or 
endothelial dysfunction.  It can promote leukocyte recruitment by upregulating the 
expression and secretion of chemokines such as chemoattractant protein-1 and 
interleuking-8 (Poddar, Sivasubramanian, DiBello, Robinson, & Jacobsen, 2001).  The 
thiol metabolite of Hcy can combine with LDL-cholesterol to produce aggregates that are 
susceptible to uptake by macrophages in the arterial intima; the ensuing foams cells can 
lead to the development of atherosclerotic plaques (McCully, 1996).  Free radicals 
formed during the oxidation of reduced Hcy may cause direct injury to endothelial cells 
(Mansoor, Bergmark, Svardal, Lonning, & Ueland, 1995; Starkebaum & Harlan, 1986) 
and result in marked platelet accumulation (McCully & Carvalho, 1987; Stamler et al., 
1993).  Prolonged exposure to Hcy in endothelial cells reduces the activity of the enzyme, 
asymmetric dimethylarginine (ADMA), responsible for the degradation of nitric oxide 
synthase (eNOS), which may contribute to impaired endothelium vasodilation (Kanani et 
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al., 1999; Tawakol, Omland, Gerhard, Wu, & Creager, 1997; Woo et al., 1997).  The 
association between elevated Hcy plasma levels and venous thrombosis, coronary heart 
disease (CHD), and atherosclerosis has been demonstrated repeatedly (Cattaneo, 1999; 
Wald, Law, & Morris, 2002; Welch & Loscalzo, 1998).  Hyperhomocysteinemia 
accounted for 13% of population attributable risk (PAR) for MI (Whincup et al., 1999) 
and for 10% of PAR for coronary artery disease (CAD) (Boushey, Beresford, Omenn, & 
Motulsky, 1995).  High plasma concentrations of Hcy were said to be associated with 
advanced atherosclerotic lesions in patients with defects in enzymes MTHFR and CBS.  
It was later observed that patients with these defects can develop severe atherosclerosis 
starting as early as childhood, and many have their first MI by the age of 20 years 
(Husemoen, Thomsen, Fenger, Jorgensen, & Jorgensen, 2003; Kluijtmans et al., 2003).    
The regulation of plasma Hcy is a complex phenotype because it is influenced by 
multiple factors.  The main environmental determinants are gender, age, renal function, 
and vitamin intake (folate, B12, and B6).  However, it has been demonstrated that genetic 
determinants play a role in the variation of Hcy levels across populations (Gaustadnes, 
Rudiger, Rasmussen, & Ingerslev, 2000; Kang, 1995; Mezzano et al., 1999; Smulders, de 
Man, Stehouwer, & Slaats, 1998), with the heritable portion of variation in Hcy across 
individuals estimated to range between 47%-70%.  The first genetic determinant 
identified for Hcy in the general population was a C to T transition at position 677, in the 
methylenetetrahydrofolate reductase (MTHFR) gene, which encodes for the MTHFR 
enzyme.  Carriers of the T allele produce a less-efficient form of the MTHFR enzyme so 
homozygotes of the T allele exhibit a moderate increase in Hcy levels (Gudnason et al., 
1998)(54-Suoto).  This polymorphism is estimated to explain 6% of the variance in 
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plasma Hcy levels (Husemoen et al., 2003) with a higher proportion explained in males 
versus females (7.3% and 5.1% respectively) (Lange et al., 2010).  Several studies have 
investigated whether genetic associations of this variant can be generalized to multiple 
populations, the clinical utility of this variant, and its prevalence across multiple 
populations 
The Coronary Artery Risk in Young Adults (CARDIA) study investigated the role 
of MTHFR and other genes involved in Hcy metabolism to determine its polygenic 
influence pre and post folic acid fortification era in the US.  In 1996, the United States 
Food and Drug Administration (FDA) mandated that all enriched grain products be 
fortified with folic acid to reduce the risk of neural tube defects in newborns. As a result, 
there was a decrease in the prevalence of hyperhomocysteinemia (Honein, Paulozzi, 
Mathews, Erickson, & Wong, 2001).  Between years 0 and 7(pre-fortification era), the 
677C>T variant was associated with Hcy in N=997 EA  (p< 0.001) and N=692 AA 
(p<0.003).  However, post fortification era (year 15), significance was only observed in 
EA (p=0.004).  Notably, another variant in the MS gene (A2756G) was associated with 
Hcy in AA both before fortification (p<0.03) and after fortification (p=0.007) (Tsai et al., 
2009).  The same group then assessed the clinical utility of the 677C>T variant in 
predicting hyperhomocysteinemia across both EA and AA.  Because the prevalence of 
the minor allele T in the 677C>T variant is so low, meaningful assessment could only be 
carried out in European Americans.  Sensitivity of MTHFR 677C>T genotyping in 
predicting hyperhomocysteinemia was >60% pre folic acid fortification and 30% post 
folic acid fortification (Tsai et al., 2009). Conversely, the specificity for 677C>T was 
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much higher (87-88%) and this percentage remained unchanged even after folic acid 
fortification (Tsai et al., 2009). 
As observed in the CARDIA study, the prevalence of MTHFR gene 
polymorphisms varies across different ethnic groups.  Esfahani, et al. determined the 
prevalence of two common polymorphisms in MTHFR (677C>T and 1298A>C) across 
women of four different ethnic groups: Hispanic women of Mexican descent, Asian 
women, African American, and European American women.  The frequency of the 
homozygous TT genotype was the highest in Mexican women and lowest in AA women 
(Esfahani, Cogger, & Caudill, 2003).  The frequency of the minor allele (C) in the 
1298A>C variant was highest in EA women.  They also assessed the frequency of 
combined genotypes for both variants.  Mexican and EA women had the highest 
frequency of combined heterozygosity (heterozygous for both mutations (17.6% and 
15.1% respectively) and AA and Asian women had the lowest (6.3% and 3.8% 
respectively) (Esfahani et al., 2003).  An international study was conducted to determine 
the prevalence of the MTHFR 677C>T variant in 7130 newborns across 16 areas in the 
Americas, Europe, Russia, China, and Australia (Wilcken et al., 2003) based on 
geographic location and ethnicity.  Based on geographic location, the prevalence of the 
MTHFR TT genotype was 10-12% in Spain, France, and Hungary; however in Finland, 
Helenski and northern Netherlands, its prevalence was between 4-6%.  In areas of 
southern Europe (Campania and Sicily), the frequency was much higher (26% and 20% 
respectively).  In New South Wales and Canada, the frequencies were 7.5% to 6% 
respectively. In the Americas, the frequency was highest in Mexico (32%)  In the US 
(Atlanta, GA), homozygosity of the T allele was more common in newborns of Hispanic 
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origin, intermediate among newborns of European ancestry in Atlanta (11%), and lowest 
among newborns of African ancestry.  It is evident that there is an impact of geographical 
and ethnic variation favoring the presence of this gene variant (Wilcken et al., 2003).  
Furthermore, this also indicates that genes that may be ethnic specific could have a 
stronger influence on Hcy levels. 
Several GWA studies have also identified other loci to affect Hcy levels.  The 
WGHS performed a GWA scan to identify novel variants that may influence Hcy levels 
in approximately 14,000 EA women.  They identified four new loci associated with 
plasma Hcy levels: carbamoyl phosphate synthetase I (CPS1) (rs7422339 at 2q34), 
methylmalonyl-CoA mutase MUT (rs4267943 at 6p12.3), nicotinamide adenine 
dinucleotide phosphate oxidase NOX4 (rs11018628 at 11q14.3), and dipeptidase 1 
(DPEP1) (rs1126464 at 16q24.3) (Pare et al., 2009).  A GWA study of Hcylevels in 
Filipino women and their offspring from the Cebu Longitudinal Health and Nutrition 
Survey (CLHNS) reported evidence of sex-dependent effects for CPS1 variant 
(rs7422339). In the pooled offspring sample, there was only evidence for association in 
the female subset but no evidence in males.  Furthermore, the direction of effect in the 
female offspring was in the same effect as the mothers (Lange et al., 2010) as well as for 
the WGHS.  To date, no GWA studies with plasma Hcy levels have been performed in a 
primarily AA dataset. 
Assessing Causality of C-reactive Protein and Homocysteine 
 
Although several studies have demonstrated associations of both CRP and Hcy with 
CVD, their roles as causal factors are still under debate.  Epidemiologic studies have tried 
 20 
 
to investigate the cause-and-effect relationship between biomarkers and CVD outcomes 
using an approach called Mendelian randomization (Lawlor, Harbord, Sterne, Timpson, 
& Davey, 2008). This approach is based on Mendel’s second law, which states that 
alleles of different genes assort independently during gamete formation (Wensley et al., 
2011).  Mendelian randomization uses common genetic polymorphisms that are known to 
influence the risk factor of interest as proxies of the risk factors that are less susceptible 
to confounding by behavioral or environmental factors (Sheehan, Didelez, Burton, & 
Tobin, 2008).  There are three key assumptions for Mendelian randomization studies: 
1. The genetic variant must be unrelated to known confounding factors for the 
relationship between the intermediate trait and the outcome. 
2. The genetic variant is associated with the outcome and this can be accurately 
quantified. 
3. For known exposure status and known confounders, the genetic variant is 
independent of the outcome (Sheehan, Meng, & Didelez, 2011). 
Therefore, in the case of CVD related biomarkers, this method should reduce 
confounding factors if the variants related to the exposure are unrelated to any other 
disease markers.   
One study using 47,000 Danish individuals from the Copenhagen General 
Population Study used Mendelian randomization to assess causality between CRP and 
atrial fibrillation.  An increase in disease risk was seen in individuals with elevated CRP 
levels within the general population but this correlation was not repeated in the portion of 
measured CRP estimated to be genetically elevated (based on genotype of previously 
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established CRP variants), suggesting that circulating CRP does not play a causal role in 
atrial fibrillation (Marott et al., 2010). A study conducted by the CRP Coronary Heart 
Disease Genetics Collaboration (CCGC) examined the role of CRP in relation to 
coronary heart disease (CHD).  Similarly, they did not identify a causal role for CRP in 
CHD.  However, this does not rule out a causal role for inflammation in CVD 
development as one or more of the assumptions made for Mendelian randomization 
analysis may not be valid.   
Mendelian randomization studies have also been conducted to investigate the 
causality between Hcy and MTHFR genotype.  A study consisting of participants from 
the National Health and Nutrition Examination Survey (NHANES) used the MTHFR 
C677T variant in Mendelian randomization to examine whether Hcy has a causal role in 
CVD mortality and all-cause mortality (Yang et al., 2012).  As expected, the MTHFR 
C677T genotype was associated with higher Hcy concentrations as well as lower serum 
folate concentrations.  Specifically, individuals with the TT genotype had a 2.2 µmol/L 
higher Hcy concentration on average than individuals with the CC genotype (Yang et al., 
2012).   A folate concentration > 3.4 ng/mL was generally associated with a lower risk of 
all-cause and CVD mortality; however, Hcy concentrations were not significantly 
associated with either of the clinical endpoints (Yang et al., 2012).  Interestingly, the 
MTHFR TT genotype was associated with a lower risk of CVD  mortality (HR=0.69, 
p=0.026) compared to the MTHFR CC genotype (control) even after stratified analyses 
by sex, ethnicity, use of folic acid supplements, serum folate deficiency status, and CVD 
status at baseline (Yang et al., 2012). A study using 12,239 postmenopausal women from 
the Netherlands, without folic acid fortification, also implemented Mendelian 
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randomization to assess for a causal relationship between the MTHFR C677T variant and 
CVD mortality.  The incident rates for CVD were highest for MTHFR CC wild types and 
lowest for TT homozygotes even after adjustment for age.  The rate ratios for CVD 
mortality were 0.7 for women with the CT genotype and 0.6 for women with the TT 
genotype compared with the CC genotype (0.8),  however there was no evidence for a 
causal relationship (P>0.05) (Roest et al., 2001).  In contrast, a study performed on 
another Dutch cohort of 666 elderly men and women (≥ 85 years) found the MTHFR 
677C>T genotype to be associated with CVD mortality (P=0.03).  However, gender 
stratified analysis revealed that the association was attenuated in women (P=0.51) and 
became more significant in men (P=0.01) (Heijmans et al., 1999).  These contradictory 
findings could suggest that the influence of the MTHFR genotype is dependent on 
differences in folate status between men and women.  
Genetic Studies 
 
The primary goal of human complex disease genetics is to identify genetic risk factors for 
common diseases such as schizophrenia, type II diabetes, and CVD (Bush & Moore, 
2012).  There are many different technologies, study designs, and analytical tools for 
identifying genetic risk factors, yet ultimately, the goal is to use these genetic risk factors 
to make predictions about disease risk and determine the biological underpinnings of 
disease susceptibility to develop new and more effective therapeutics (Bush & Moore, 
2012). 
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Single nucleotide polymorphisms 
 
The unit of genetic variation is the single nucleotide polymorphism (SNP).  SNPs are 
single base-pair changes in the DNA sequence that occur with high frequency in the 
human genome (Genomes Project et al., 2010).  SNPs are typically used as markers of a 
genomic region where most of these markers have minimal impact on biological systems.  
However, SNPs can have functional consequences some of which include an amino acid 
change, changes to mRNA transcript stability, and transcription factor binding affinity 
(Griffith et al., 2008).  SNPs typically have two alleles meaning there are two commonly 
occurring base-pair possibilities for a particular SNP location.  Mendelian diseases are 
usually caused by a single, rare genetic mutation that induces a detrimental change to 
protein function leading to the diseased state, with high penetrance. For common 
complex disease, however, SNPs that are identified are often not themselves functional 
and are merely tagging variants with usually very modest effects, and there are often 
many such variants spread across the genome.     
Linkage Disequillibrium 
 
Linkage disequilibrium (LD) is a property of SNPs on a contiguous stretch of a genomic 
sequence that describes the degree to which a SNP allele is inherited or correlated with an 
allele of a different SNP.  The concept is closely related to chromosomal linkage, which 
relates how two markers on a chromosome remain physically joined through multiple 
family generations.  Generally, recombination events within a family from generation to 
generation break apart chromosomal segments (Bush & Moore, 2012).  LD decreases 
through increasing generations of random mating, which continue to break apart 
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contiguous chromosomal segments.  Under random mating and no selection or migration, 
eventually all of the alleles in a population will reach linkage equilibrium or become 
independent of each other.  
Patterns of LD can help identify founder effects (Bush & Moore, 2012).  The rate 
of LD decay is dependent on multiple factors including population size, number of 
founding chromosomes, and the number of generations for which the population has 
existed (Bush & Moore, 2012). As such, different subpopulations, or ethnic groups, have 
varying degrees of LD.  Populations of African descent have smaller regions of LD due 
to the accumulation of more recombination events. European and Asian descent 
populations relatively recently descended from sub-African populations; thus, these 
groups on average have larger regions of LD due to less recombination (Bush & Moore, 
2012).   
Two commonly used measures of LD are D’ and r2 (Devlin & Risch, 1995; 
International HapMap, 2005); yet for the purposes of genetic analysis, LD is generally 
reported in terms of r
2
, a statistical measure of correlation (Fallin & Schork, 2000).  SNPs 
that are selected specifically to capture the variation at nearby sites in the genome are 
called tag SNPs because alleles for these SNPs tag the surrounding stretch of LD.  Based 
on analysis of data from the HapMap project, >80% of commonly occurring SNPs in 
European descent populations can be captured using a subset of approximately 500,000 
to one million SNPs across the genome (M. Li, Li, & Guan, 2008).  SNP-trait 
associations can result from either direct or indirect association (Hirschhorn & Daly, 
2005).  In a direct association, the SNP influencing a biological system that leads to the  
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phenotype is directly genotyped.  In an indirect association, the influential SNP is not 
directly genotyped but rather a surrogate for the causal SNP is studied (Hirschhorn & 
Daly, 2005).  Due to these two possible outcomes, a significant SNP association should 
not be assumed as causal (Bush & Moore, 2012).   
Candidate gene studies 
 
Candidate gene studies investigate genes that are selected for their potential role in the 
etiology of the disease or trait based on known biology or previous studies that have 
identified the gene in relation to the disease or phenotype of interest.  Thus, a candidate-
gene study takes advantage of both increased statistical efficiency of the association 
analysis of complex diseases and the biological understanding of the phenotype and the 
genes under consideration (Tabor, Risch, & Myers, 2002).  The selection of candidate 
genes is very similar to the identification and ranking of risk factors in an 
epidemiological study (Terwilliger & Goring, 2000).  The first step is to examine 
published studies of the phenotype of interest.  Evidence can be evaluated for the 
involvement of specific genes, which may influence the phenotype of pathological 
disease models or expression studies that can provide information about the tissues and 
cells that are involved in the disease (Perou et al., 2000; Scherf et al., 2000; Welsh et al., 
2001).  Subsequently, the range of possible hypotheses, the size of the study population, 
and the magnitude of the effect of the genes is also evaluated (Long & Langley, 1999).   
The next step is to prioritize SNPs based on their functionality.  Theoretically, it is 
desirable to only study polymorphisms that are likely to affect the function of a protein or 
its expression.  However, information about the functionality of all variants is often 
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difficult to obtain or not established. In addition to considering the function of 
polymorphisms, it is also important to consider their frequency in the population being 
tested for association.  The statistical power to detect a significant association depends on 
the effect size of the association and the frequency of the allele of interest (Lalouel & 
Rohrwasser, 2002; Long & Langley, 1999; N. Risch & Merikangas, 1996).  SNPs with 
very low allele frequencies would need to have very large relative risks associated with 
them to be detected in a candidate gene study; therefore, SNPs with frequencies of at 
least 5% are generally more likely to be useful (N. J. Risch, 2000).  Because variants with 
severe functional consequences tend to be much less frequent in the population, more 
common variants with less severe consequences may have to be given a higher priority in 
candidate-gene study.  Lastly, another important consideration in selecting SNPs is 
whether there is significant LD in the candidate gene within the study population.  
Determining LD in a small pilot sample can help to optimize SNP selection and provide 
information about possible or analysis (Lewontin, 1988).  If several SNPs in a gene or 
gene region are in high LD, it is possible to infer some of the genotypes based on the 
genotypes of a subset of SNPs.  Therefore, the total number of genotypes assayed can be 
reduced by selecting SNPs that are most likely to be functional from a set of SNPs that 
are in significant LD (Drysdale et al., 2000; Subrahmanyan, Eberle, Clark, Kruglyak, & 
Nickerson, 2001). 
A limitation of candidate gene studies is that the current knowledge regarding 
disease pathologies as well as gene functions may not be sufficient to allow for optimal 
selection of genes.  However, candidate gene studies can be a cost-efficient and powerful 
approach, particularly in the following cases: to follow up genes identified in one 
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population in additional populations; to fine-map genes where associations with likely 
non-causal variants have previously been reported; and to evaluate gene-by-environment 
interactions in settings that are biologically plausible. 
Genome-wide association studies/Large SNP panels 
 
The idea that common diseases have a different underlying genetic architecture than rare 
disorders, coupled with the discovery of several susceptibility variants for common 
diseases with a high minor allele frequency, led to the development of the common 
disease/ common variant (CD/CV) hypothesis (Reich & Lander, 2001).  The hypothesis 
simply states that common disorders are likely influenced by multiple genetic variants 
that are each common in the population.  Genome-wide association studies (GWAS), 
which consist of evaluating panels of tag SNPs across the entire genome for association 
with the trait of interest, are now widely used to identify susceptibility loci and operate 
under the CD/CV hypothesis.  However, there are several key inferences made in the use 
of this particular hypothesis.  
1. If the common genetic variants influence disease, the effect size for any one 
variant must be small relative to that found for rare disorders.   
2. Second, if common alleles have small genetic effects, or low penetrance, but 
common disorders show heritability, then multiple common alleles must 
influence disease susceptibility.  
Essentially, if the allele of a single SNP incurs only a small degree of risk, that SNP only 
explains a small proportion of the total variance due to genetic factors.  Per se, the total 
genetic risk due to common genetic variation must be spread across multiple genetic 
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factors (Bush & Moore, 2012).  As such, common variants cannot have high penetrance 
(Bush & Moore, 2012). 
A systematic approach is needed to examine much of the common variation in the 
human genome.  First, the location and density of commonly occurring SNPs is needed to 
identify the genomic regions. Second, population-specific differences in genetic variation 
must be cataloged so that studies of phenotypes in different populations can be conducted 
under the proper study design.  Finally, correlations among common genetic variants 
must be determined so that genetic studies do not collect redundant information (Bush & 
Moore, 2012).  The International HapMap Project was designed to carry out such an 
approach. The project uses a variety of sequencing techniques to discover and catalog 
SNPs in the following populations: European, Yoruba of African origin, Han Chinese 
from Beijing, China, and Japanese from Tokyo, Japan (International HapMap, 2005; 
Ritchie et al., 2010).    
Exploitation of LD patterns allows for the use of a method called imputation 
where GWAS datasets are imputed to generate results for a common set of SNPs without 
directly genotyping (Y. Li, Willer, Sanna, & Abecasis, 2009). The concept is similar in 
principle to haplotype phase algorithms, where the contiguous set of alleles lying on a 
specific chromosome is estimated.  Genotype imputation extends this methodology to 
populations.  First, a collection of shared haplotypes within the study sample is computed 
to estimate haplotype frequencies among previously genotyped SNPs.  Next, phased 
haplotypes from the study sample are compared to reference haplotypes from a panel of 
much more dense SNPs, such as HapMap or 1000 Genomes.   
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The study sample haplotypes may match multiple reference haplotypes so the 
surrounding genotypes are given a score of probability instead of actually assigning the 
imputed SNP a particular allele (i.e. A).  The probabilities for each allele at each SNP are 
estimated, for example (0.85 A, 0.12 C, 0.03 T), based on estimated haplotype 
frequencies (Biernacka et al., 2009; Browning & Browning, 2009; Guan & Stephens, 
2008; B. N. Howie, P. Donnelly, & J. Marchini, 2009).  
 Often the effects identified in an initial GWAS suffer from the winner’s curse, 
where the observed effect is likely stronger in the discovery GWAS sample as compared 
to the general population.   Therefore, the gold standard for the validation of any genetic 
study is replication in an additional sample.  There are several criteria, which have been 
outlined by a working group from the National Human Genome Research Institute 
(NHGRI), that establish a positive replication (Studies et al., 2007).  First, replication 
studies should have sufficient sample size to detect the effect of the susceptibility allele.  
Second, they should be conducted in an independent dataset drawn from the same 
population as GWAS, in an attempt to confirm the effect of the GWAS target population.  
Replication of a significant result in an additional population (other than the target) is 
sometimes called generalization meaning the genetic effects are relevant across multiple 
populations.  Third, identical phenotype criteria should be used in both the GWAS and 
replication study. Lastly, a similar effect should be seen in the replication set from the 
SNP, or a SNP in high LD with the GWAS-identified SNP (Bush & Moore, 2012). 
 The results of multiple GWAS studies can be pooled to perform a meta-analysis.  
Meta-analysis techniques were developed to examine and refine significance and effect  
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size estimates from multiple studies.  A fundamental principle in meta-analysis is that all 
studies are testing the same hypothesis; therefore, the general design of each study should 
be similar.  Quality control procedures that determine which SNPs are included; covariate 
adjustments; and the measurement of clinical covariates and phenotypes should all be 
standardized.  Additionally, the sample sets across all studies should be independent. The 
most critical standard is to verify that all studies report results relative to a common effect 
or coding allele.  If one study reports reference allele A, whereas, the other reports 
reference allele B, the meta-analysis result may not be significant because the effects will 
nullify each other (Sanna et al., 2008; Willer et al., 2008).  Because it is rare to find 
multiple studies that match all this criteria, heterogeneity is often statistically quantified 
to determine the degree to which the studies differ (Huedo-Medina, Sanchez-Meca, 
Marin-Martinez, & Botella, 2006). 
Meta-analysis 
 
Recognizing the need and benefits of data sharing, GWAS investigators have formed 
various networks or consortia to share data on the same disease or related disorders 
(Dehghan et al., 2011; Ioannidis, 2008; Pankow et al., 2001; Sobrin et al., 2011).  The 
general perception is that a mega-analysis (raw, individual data) is statistically more 
efficient because it utilizes much more detailed information.  However, a caveat for 
obtaining such data is that it is costly and time-consuming.  Therefore, another preferred 
method for pooling data is conducting a meta-analysis (Lin & Zeng, 2010).  Any genetic 
effect produced by the accumulation of individual raw data in a mega-analysis or the 
pooling of data in a meta-analysis have approximately the same variance (Lin & Zeng, 
2010). 
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 A meta-analysis is a method of systematically combining pertinent and qualitative 
and quantitative study data from several selected studies to develop a single conclusion 
that has greater statistical power (Bahekar, Singh, Saha, Molnar, & Arora, 2007).  This 
conclusion is statistically stronger than the analysis of any single study due to increased 
numbers of subjects, greater diversity among subjects, or accumulated effects and results 
(Bahekar et al., 2007).  The advantages of conducting a meta-analysis are greater ability 
to gain statistical power; establishing a confirmatory data analysis; greater ability to 
extrapolate to the general population affected; and this analysis is considered to be an 
evidence-based resource (Ageno, Becattini, Brighton, Selby, & Kamphuisen, 2008).  
However, one of the major concerns for perform such analysis is publication bias of 
literature results.  This bias can be reduced by systematically selecting studies, which use 
a standardized phenotype and similar statistical methodologies (i.e. models, covariate 
adjustments) (Bush & Moore, 2012).  Additionally, the creation of consortiums can also 
reduce this bias.  In a consortium setting, the same covariate adjustments can be made 
within each study and the covariate-adjusted estimates of genetic effects can then be 
combined through a meta-analysis (Lin & Zeng, 2010). 
Utility of multi-ethnic samples in genetic studies  
 
It has been demonstrated that the use of non-European samples can improve the power to 
detect susceptibility loci (N.A. Rosenberg et al., 2010).  Pulit, et al. showed that minor 
allele frequencies differences across populations can lead to dramatically different 
statistical power to detect associations for those populations (Pulit, Voight, & de Bakker, 
2010).   
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Because allele frequencies differ across populations, the incorporation of multiple ethnic 
samples can help elucidate ethnically distinct loci and/or variants.  For example, the SNP 
(rs2283228) in the KCNQ1 locus, associated with Type 2 diabetes, has a minor allele 
frequency of ~40% in East Asian populations but only ~5% in European populations 
(McCarthy, 2008; Unoki et al., 2008; Yasuda et al., 2008). Similar to allele frequencies, 
patterns of linkage disequilibrium (LD) vary across populations; thus the study of 
multiple populations can facilitate fine-mapping that could uncover a true causal 
polymorphism.  A study by Shriner, et al., using participants of African and Asian 
ancestry, localized a region in chromosome 1 consisting of loci previously identified in 
EAs to be associated with human height (Shriner et al., 2009). It should be noted, 
however, that this approach makes the assumption that the same causal variant is 
underlying the association across ethnicities, which may not be accurate in some cases. 
 
Controlling for population substructure 
 
Stratification in genetic studies is often attributed to differences in population genetic 
structure and substructure (Tian, Gregersen, & Seldin, 2008).  If these ancestry 
differences are unaccounted for, it can lead to false positive findings.  Even when studies 
are restricted to a single continental origin, many false-positive results may still be 
observed due to subtle differences in ethnic make-up (Clayton et al., 2005; Marchini, 
Cardon, Phillips, & Donnelly, 2004; A. L. Price et al., 2006).  To address this issue, 
statistical methods can be applied to discern and correct for these differences. 
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 Generally, three approaches are used to correct for population substructure.  
These methods are structured association tests; principal component analyses (PCA), and 
multidimensional scaling (MDS).  Structured association depends on applying 
information from model-based or distance-based clustering algorithms.  The model-based 
STRUCTURE program (Falush, Stephens, & Pritchard, 2007; Pritchard, Stephens, & 
Donnelly, 2000) can be used to perform tests conditional on group (or ethnic) 
membership.  This membership is determined using a Bayesian clustering algorithm that 
fits the data to the number of specified cluster groups.  This method tests the null 
hypothesis, which is that there is no dependence of allele frequencies on phenotypes 
within each group; however, the limitation of this tests is that it requires an estimation on 
the number groups being tested and is computationally intensive (Tian, Gregersen, et al., 
2008). When Euclidean distance is used, classical metric MDS is the same as PCA.   
Both PCA and MDS can infer a continuous axis of genetic variation independent of 
assigning individuals to various subpopulations or groups.   
Both approaches reduce high-dimensional data to smaller numbers of dimensions that 
intuitively group patterns together based on the observed data (Tian, Plenge, et al., 2008).  
The program EIGENSTRAT (A.L. Price et al., 2006) calculates ancestry-adjusted 
genotypes and phenotypes using the continuous axis of variation from PCA to compute 
the association statistic (Tian, Gregersen, et al., 2008); however, the number of principal 
components (PCs) that need to be examined will vary across datasets.  Therefore, to 
determine the number of PCs that should be considered, a genomic control parameter 
should be implemented (Tian, Plenge, et al., 2008). 
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 Substantial differences in allele frequencies within different continental 
populations have been reported (N. A. Rosenberg et al., 2002).  In general, the number of 
SNPs showing large allelic frequency differences between major continental populations 
are an order of magnitude greater than those seen within continental populations.  Thus, 
the largest source of type 1 errors will be caused by differences in the distribution of 
ancestry from major continental populations.  Self-identification of ancestry usually 
reduces this problem; however, the presence of admixture can lead to bias results (N. A. 
Rosenberg et al., 2005).  PCA and MDS will distinguish an individual with substantial 
admixture; however the use of ancestry informative markers (AIMs) can be used to verify 
self-identification of ethnicity (Tian, Gregersen, et al., 2008). 
Gene-environment interactions 
 
The concept that the etiology of most common diseases involves not only discrete genetic 
and environmental factors but the interaction between the two is increasingly being 
accepted (Garrod, 1996).  In the context of genetics and epidemiology, the study of gene-
environment interactions is extremely useful.  If we estimate only the separate 
contributions of genes and environment to a disease, ignoring their interactions, we will 
incorrectly estimate the proportion of the disease that is explained by genes, environment, 
and their joint effect (Hunter, 2005).  Ultimately, understanding gene-environment 
interactions might further allow the use of individualized preventative measures, in 
addition to offering personalized therapeutics post diagnosis (Hunter, 2005).   
 Screening a larger number of potential interactions in datasets with a large 
number of genotypes and many variables of exposure greatly increases the chances of 
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identifying a false-positive (T. R. Rebbeck, Spitz, & Wu, 2004).  In addition, most 
studies do not individually have sufficient sample sizes for detection modest interactions 
(T. R. Rebbeck et al., 2004).  Restricting the search for gene-environment interactions to 
biologically plausible candidate genes and utilizing meta-analysis across studies 
addresses these issues.   
Cigarette smoking and cardiovascular disease 
 
Smoking causes 140,000 premature deaths from cardiovascular disease annually in the 
US representing about 30% of all smoking-related deaths (Burns, 2003).  While the 
specific mechanisms are not understood, cigarette smoking acts synergistically with other 
cardiovascular risk factors to increase CVD morbidity and mortality (Burns, 2003; 
Unverdorben, von Holt, & Winkelmann, 2009).  Epidemiological studies strongly support 
the idea that cigarette smoking in both men and women increases the incidence of MI and 
fatal CAD.  Current smoking is associated with an eighty percent increase in CAD risk 
and second-hand tobacco exposure, which is approximately 1/100
th
 of that of an active 
smoker, is associated with a 30% increase in CAD risk (Glantz & Parmley, 1991; Law, 
Morris, & Wald, 1997).  Although evidence has suggested a link between cigarette smoke 
exposure and CVD, the exact components of cigarette smoke and the mechanisms 
responsible for the association have not been clearly elucidated (Ambrose & Barua, 
2004). 
Vasomotor dysfunction, inflammation, and modification of lipids precede the 
clinical manifestations of atherosclerosis (Clarkson, Weingand, Kaplan, & Adams, 1987; 
Ross, 1999).  Endothelial dysfunction results in the impairment of vasodilatory function, 
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which is one of the earliest manifestations of atherosclerotic changes in the blood vessel. 
The endothelium produces its vascular effects via the release several small molecules 
including nitric oxide (NO), prostacyclin, tissue plasminogen activator (tPA), and 
plasminogen activator inhibitor-1 (PAI-1) (Benowitz, 2003). Cigarette smoking may alter 
these chemicals, which could result in vasoconstriction (Shen, Rattan, Sultana, & Kalra, 
1996).  Smokers without atherosclerosis have coronary vasoconstrictor effects in the 
endothelium that in the presence of normal function would produce vasodilation; these 
effects are greater in the presence of hypercholesterolemia (Adams, Jessup, & 
Celermajer, 1997; Weber, Erl, Weber, & Weber, 1996).  Several studies indicate that 
cigarette smoking causes an approximate 20%-25% increase in the peripheral blood 
leukocyte count (C. J. Smith & Fischer, 2001) and is associated with an increased level of 
multiple inflammatory markers including CRP, IL-6, and TNFα in both male and female 
smokers (Bermudez, Rifai, Buring, Manson, & Ridker, 2002; Tappia, Troughton, 
Langley-Evans, & Grimble, 1995; R. P. Tracy et al., 1997).  Elevations of 
proinflammatory cytokines increase leukocyte recruitment to the site of endothelial injury 
(Bermudez et al., 2002; Mazzone et al., 2001).   Cigarette smoking also causes activation 
of proatherogenic molecules leading to an alteration in intercellular interactions.  
Cigarette smoking exposure was associated with 70% to 90% increase in the adherence 
between human monocytes and human umbilical vein endothelial cells (HUVECs) due to 
increased expression of adhesion molecules on the surface of both monocytes and 
HUVECs (Kalra et al., 1994).   
Although cigarette smoking is extraordinarily hazardous, many smokers do not 
appear to suffer injury from their addiction.  Fifty-percent of life-long smokers die 
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prematurely from smoking-related diseases, whereas, 50% do not (Benowitz, Jacob, 
Jones, & Rosenberg, 1982).   Moreover, some smokers develop severe CVD, which may 
result in an early death but some appear to be resistant to CVD despite a history of heavy 
smoking (J. Wang et al., 2010).  These sources of variability may be due to genetic 
modifications of risk which may both enhance susceptibility and protect against disease. 
 Most of the literature on genetic influences of smoking-induced disease in 
humans has largely been focused on a family of genes called the glutathione-S-
transferases (GSTs).  GSTs have been one of the primary classes of genes evaluated as 
they are involved in the detoxification and/or activation of some chemicals in cigarette 
smoke(T.R. Rebbeck, 1997).  GSTs catalyze the conjugation of glutathione, an important 
antioxidant, to a variety of electrophilic compounds and peroxidases (Anderson, 1998). 
This family of genes is divided into six classes where the mu and theta classes seem to 
contribute primarily to the interindividual differences in pathology or clinical response 
(Townsend).  
The mu (GSTM1) and theta (GSTT1) class of GST have a null phenotype (often 
designated as GSTM*0 and GSTT1*0) whereby individuals do not express the 
catalytically active enzyme.  The lack of enzymatic activity is associated with an increase 
risk to a variety of cancers and heart diseases (Townsend, Tew, & Tapiero, 2003).  The 
GSTM1*0 allele is observed in ~50% of the European American population and is 
associated with an increased risk of lung, colon, and pulmonary asbestosis (C. M. Smith 
et al., 1994; Strange, Jones, & Fryer, 2000).  In contrast, the GSTT1*0 allele varies 
between ethnic groups but is most prevalent in Chinese populations (65%) and lowest in  
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Mexican American populations (9%) (Nelson et al., 1995).  The GSTT1 null phenotype is 
associated with an increase in tumors of the head, neck, and oral cavity (Chenevix-
Trench, Young, Coggan, & Board, 1995; Strange, Lear, & Fryer, 1998).  Thus, GST-
related genes are ideal candidates for assessing as potential modifiers of the effect that 
smoking behavior has on inflammatory CVD biomarkers, such as CRP.     
   
 
 
 
 
 
 
CHAPTER 2 
LARGE MULTI ETHNIC CANDIDATE GENE STUDY FOR C-REACTIVE 
PROTEIN LEVELS  
 
  C-reactive protein (CRP) is a pentameric acute-phase protein that is a hallmark of 
systemic inflammation.(P.M. Ridker, 2010)  Vascular inflammation is thought to play a 
role in the development and progression of atherosclerosis, ultimately leading to plaque 
rupture and cardiovascular disease (CVD) events such as myocardial infarction.(Robbie 
& Libby, 2001)   Associations between CRP and CVD outcomes have been remarkably 
consistent despite varying study designs, target populations, and case classification 
methods.(Pankow et al., 2001) Observational studies have shown increased levels of CRP 
to be present in individuals with factors such as older age, obesity, (Koenig et al., 1999) 
female sex,(Slade et al., 2000) smoking,(Harris et al., 1999) diabetes, atherosclerotic  
CVD,(Mendall et al., 1996; R.P. Tracy et al., 1997) sleep curtailment (van Leeuwen et 
al., 2009) and sleep apnea.(Larkin et al., 2005) Familial studies have reported heritability 
estimates for CRP levels of 35-40%, (Schnabel et al., 2009) supporting that genetic 
factors are likely to influence the variation of CRP levels in response to CVD risk 
factors.(Pankow et al., 2001)  
 Multiple candidate gene and genome-wide association studies (GWAS) have been 
performed for CRP resulting in several reported associated loci.  These associations 
include genes known to be involved in the regulation of inflammatory and metabolic 
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pathways, some of which were not previously known to directly influence CRP levels.  
The Women’s Genome Health Study identified single nucleotide polymorphisms (SNPs) 
associated with CRP in the leptin-receptor gene (LEPR), glucokinase regulatory protein 
(GCKR), and hepatic transcription factor gene (HNF1A).(A.P. Reiner et al., 2008)  
Recently, a GWAS meta-analysis of participants of European ancestry confirmed 
association of previously identified loci with CRP and introduced 11 novel loci, including 
NLRP3, HNF4A, RORA, IRF1, and IL1F10.(Dehghan et al., 2011)  To our knowledge, 
only two published GWASs for CRP in individuals of African ancestry have been 
conducted (Doumatey et al., 2012; A. P. Reiner et al., 2012), and the first was based on a 
relatively small cohort of individuals.(Doumatey et al., 2012) This earlier study identified 
several variants in the CRP gene that were associated with CRP, but no other loci were 
statistically significant. (Doumatey et al., 2012) The latter study, which included 8,280 
African American (AA) women from the Women’s Health Initiative (WHI) study, also 
identified a number of variants associated with CRP in the CRP gene as well as 
significant evidence for associations in or near IL1F10/IL1RN, TREM2, HNF1A and 
TOMM40/APOE.(A. P. Reiner et al., 2012) 
We sought to extend what is known regarding the genetic underpinnings of CRP 
by performing a multi-ethnic meta-analysis, including individuals of both African and 
European ancestry genotyped across a densely covered gene-based array.  Participants for 
the primary analyses came from eight community-based cohorts from the Candidate 
Gene and Association Resource (CARe) consortium (AAs and European Americans 
[EAs]), WHI (EAs) and the Cooperative Health Research in the Region of Augsburg 
(KORA) study (Europeans). All participants had available genotype data from the 
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ITMAT Broad-CARe (IBC) Chip, a custom 50,000 SNP gene-centric array having dense 
coverage of over 2,000 candidate genes within CVD related pathways. Additional AA 
participants from WHI study were used as a follow-up sample for interesting findings. 
Results  
Characteristics of the 7,584 AA and 29,975 European-ancestry study participants 
from CARe, WHI and KORA can be found in Table 2.1.   
African Americans 
Four loci reached study-wide significance (p<2.2x10
-6
) in AAs (Table 2.2), 
including three loci reported in previous GWASs for CRP in individuals of European 
descent (CRP, IL6R, APOE). The fourth significant result, at rs3211938 in the gene 
encoding the cluster differentiation 36-membrane protein (CD36; p= 1.4x10
-6
), has not 
been reported previously. A locus zoom plot of the CD36 region is presented in Figure 1, 
demonstrating the focused association at rs3211938.  We further tested this SNP using 
imputed exome sequencing data in an independent sample of 8,041 African Americans 
women from WHI. The association was confirmed, with the minor allele of CD36 
rs3211938 associated with 0.128 (+/- 0.030) lower CRP levels (p=1.8x10
-5
). Together, in 
a combined meta-analysis of CARe and WHI African American participants, results at 
CD36 rs3211938 reached genome-wide significance (p =1.5x10
-10
). Of note, CD36 
rs3211938 was not studied in the recent WHI GWAS. (A. P. Reiner et al., 2012) There 
was no evidence for any heterogeneity in the results across the AA cohorts for any of the 
four significant loci (Table 2.2).  
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Out of the five loci previously reported to be associated with CRP in AA women 
by Reiner, et al., we had good proxies for SNPs at genes CRP and TOMM40 but no 
available satisfactory proxies for the remaining gene regions (HNF1A, ILF10/IL1RN, and 
TREM2) (A. P. Reiner et al., 2012).  
Our top result occurred at CRP rs3093058 (p=4.2x10
-71
) (Table 2.2), which is in 
strong linkage disequilibrium (LD) with our best available proxy for rs16827466 
(r
2
=0.89) (based on 1000 Genomes data in subjects of African ancestry (YRI)), the top 
variant reported by Reiner et al.(A. P. Reiner et al., 2012) Our most significant result at 
APOE was for SNP, rs769450 (p=2.0x10
-6
), which is in modest LD (r
2
=0.28) with the top 
SNP, rs1160985 in nearby TOMM40, reported by Reiner et al.  However, our best proxy 
for SNP rs1160985 (rs405509, r
2
=0.66) demonstrated nominal evidence for association 
with CRP (p=1.2x10
-4
). We had poor proxies available for the top SNPs reported for the 
other three significant loci in Reiner et al. Our best proxy for IL1F10/IL1RN rs6734238, 
(rs17042795, r
2
=0.28) demonstrated a trend towards association (p=0.068), as did our  
best proxy for HNF1A rs7979473 (rs1169293, r
2
=0.33, p=0.052). We did not find any 
evidence for an association at our best proxy (rs6933067, r
2
=0.39, p=0.14) for the 
reported novel TREM2 SNP rs7748513 association. 
 
Combined Race Meta-Analysis 
 We observed significant signals (p<2.2x10
-6
) at 13 loci, including seven loci 
widely reported to be associated with circulating CRP levels (CRP, 
TOMM40/APOE/APOC1, HNF1A, LEPR, GCKR, IL6R, BAZ1B/ BCL7B and IL1RN) and  
 43 
 
two (NLRP3 and HNF4A) recently reported as significant by the Cohorts for Heart and 
Aging Research in Genomic Epidemiology (CHARGE) consortium (Table 2.3). We 
identified a CRP-associated locus, the aryl hydrocarbon receptor nuclear translocator like 
gene (ARNTL), that was reported by CHARGE to be “suggestive” (i.e. nominally 
associated with p<1.0x10
-5
 with CRP levels), and two novel loci, the gene encoding the 
ribosomal protein S6 kinase (RPS6KB1) and CD36. 
 The direction and size of the effects were largely consistent between AAs and 
subjects of European descent for most of these 13 loci (Table 2.3).  In some cases, the 
frequency of the minor allele was considerably different between the populations, which 
could largely explain the absence of significant evidence for association in one 
population or the other. One SNP, rs2075650 in TOMM40, had highly discrepant results 
between AAs and subjects of European descent. There was no evidence for any 
association for the variant in AAs; in fact there was a near trend for an effect in the 
opposite direction as was observed in subjects of European descent. Interestingly, both 
AAs and subjects of European descent had evidence for association at nearby SNP 
rs769450 (AAs see Table 2; Europeans, beta (SE) =0.033(0.009), p=1.0x10
-4
). The two 
variants are in weak LD (estimated r
2
 in YRI = 0.088, r
2
 in CEU = 0.13) in populations of 
African and European ancestry. 
 
Analyses of European Americans not included in CHARGE consortium  
A subset of the current study samples was also included in the CHARGE report, 
which included ~66,000 subjects of European descent with CRP and genotype 
measurements.(Dehghan et al., 2011) Genotype data used in the CHARGE report were 
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obtained across a variety of genome-wide marker platforms; genotype imputation was 
used to probabilistically infer missing genotype data for SNPs in the HapMap database.  
The current study, which includes ~38,000 samples, has ~22,000 overlapping European-
ancestry samples with the CHARGE report. Notably, no African Americans were 
included in the CHARGE report.   
Focusing on the CHARGE EA sample (n~16,000) not previously identified in 
CHARGE, we identified significant evidence for six loci (CRP,TOMM40/APOE/APOC1, 
HNF1A, LEPR, GCKR, IL6R) widely recognized to be associated with CRP (Table 2.4). 
We found evidence supporting two new reported associations in the CHARGE report 
(HNF4A rs1800961 p=5.4x10
-4
; NLRP3 rs12239046 p=0.011), providing, to our 
knowledge, the first reported confirmation for these findings. We also found indirect 
evidence, through a proxy SNP, supporting another novel CHARGE finding, rs13233571 
in the BAZ1B/BCL7B gene cluster. We found nominal evidence at BAZ1B rs714052 
(p=7.6x10
-3
), which is in strong LD with the reported CHARGE SNP (r
2
=0.93 in CEU 
HapMap samples). Additionally, we found indirect evidence, through proxy SNP 
rs6486121 (p=0.0025), supporting an association at rs6486122 in ARNTL reported to be 
nominally significant in CHARGE.  Interestingly, in this non-overlap EA sample, there 
was no evidence of association at RPS6KB1 rs1292034 (p=0.41), which we identified as 
a novel locus in our combined meta-analysis.   
Discussion 
 
 We performed a dense candidate gene-based scan of approximately 50,000 SNPs 
covering approximately 2,000 gene regions in a combined bi-racial sample of ~32,000  
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individuals.  We observed significant evidence for 7 loci widely reported to be associated 
with CRP, which include: CRP, TOMM40/APOE/APOC1, HNF1A, LEPR, IL6R, GCKR, 
IL1RN.  We also found IBC array-wide significant evidence for association at HNF4A, 
NLRP3, and BAZ1B/BCL7B, loci that were reported to be significantly associated with 
CRP in the recent CHARGE report. Analyses based on an independent subset of samples 
not included in the CHARGE report provide supporting evidence for these associations. 
We also found significant evidence for association at ARNTL, a locus reported as 
suggestive in the CHARGE report.  Finally, we identified two novel loci, CD36 and 
RPS6KB1, which have not been previously reported to be significantly associated with 
CRP. The CD36 association at rs3211938 is specific to African Americans.  A meta-
analysis at rs3211938 including an additional sample of 8,041 African American women 
from WHI resulted in a genome-wide significant association.  
The CD36 gene encodes a cellular receptor that facilitates fatty acid uptake and 
the utilization of key metabolic tissues.(Coburn et al., 2000; Tanaka et al., 2001)  
Individuals with mutations in CD36 have a defective FA uptake which could result in a  
poor metabolic profile and elevated serum lipid levels. (Miyaoka et al., 2001; Tanaka et 
al., 2001) Patients with elevated lipid levels (i.e. LDL cholesterol) are more likely to 
develop atherosclerosis, which most broadly defines cardiovascular disease risk. Various 
scavenger receptors have been recognized for their role in mediating the uptake of 
oxidized LDL (ox-LDL) leading to the formation of foam cells which is a precursor step 
in the development of atherosclerotic lesions.(Goyal et al., 2012) CD36 is a scavenger 
receptor involved in the uptake of these oxidized lipids and thus plays a role in the 
formation of atheroma.(Goyal et al., 2012).  Interestingly, an in vitro experiment showed  
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that the addition of CRP to ox-LDL in a cell culture system stimulated foam cell 
formation suggesting that CRP may have an active role in enhancing foam cell formation. 
(Ji, Wu, Potempa, Qiu, & Zhao, 2006)  Together, these findings suggest that CRP and 
CD36 may have a cooperative role in atherogenesis. 
 The influence of natural selection, linked to malaria susceptibility, has resulted in 
the high genetic variation of CD36 in populations of African descent (Aitman et al., 
2000; Omi et al., 2003); as a result, CD36 mutations are more commonly observed in 
African populations versus populations of primarily European descent. (Love-Gregory et 
al., 2008). The link to malaria susceptibility results in the gene’s role as a receptor for 
Plasmodium falciparum infected erythrocytes, which is found in malaria patients.  
Variants in this gene have also been reported be associated with metabolic syndrome, 
(Love-Gregory et al., 2008)  HDL cholesterol levels (Love-Gregory et al., 2011; 
Musunuru et al., 2012), and abnormal serum FA. (Handberg, Levin, Hojlund, & Beck-
Nielsen, 2006; Silverstein, 2009; Sun et al., 2010)  A study using African American 
participants from HyperGEN demonstrated that CD36 variants account for ~3.4% of 
inter-individual HDL variability in the study population.(Coon et al., 2001)  The 
nonsense variant rs3211938 identified in our analysis encodes for a truncated form of the 
CD36 protein and causes an amino acid change from threonine to glycine.  This variant 
has only been identified in populations of African descent, having thought to arise due to 
positive selective pressure, and thus its predictive impact on CD36 expression would not 
apply to other populations.(Fry et al., 2009; Sabeti et al., 2006) In a recent study by Love-
Gregory, et al., the minor allele (G) for rs3211938 was associated with increased HDL 
and reduced CD36 protein expression on monocytes. (Love-Gregory et al., 2011)  The 
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same coding allele (G) for rs3211938 was associated with lower CRP levels in our 
analysis, suggesting that CD36 SNPs may elucidate a biological link between CRP and 
HDL levels.  A GWAS study on platelet count and mean platelet volume of 16,388 
African American individuals identified novel associations at two intronic SNPs at the 
CD36 gene (Qayyum et al., 2012).  Previous evidence has demonstrated that one of the 
variants (rs17154155) is associated with platelet function as well as platelet expression of 
CD36 (Ghosh et al., 2011; Jones et al., 2009), and interestingly, rs17154155 happens to 
also be in LD with the rs3211938 variant associated with CRP levels in our analysis (r
2= 
0.271).  Further analysis on less common CD36 variants in African Americans from the 
National Heart Lung and Blood Institute Exome Sequencing Project found rs3211938 to 
be associated with lower platelet count in this population (P. L. Auer et al., 2012).  Taken 
together these results also suggest the potential for CD36 variants to be used as a 
predictive tool for CVD risk in African Americans (Love-Gregory et al., 2011).  
A recent study from the CARe consortium, using the same AA participants 
included in this study, also found strong evidence for an association between HDL levels 
and CD36 rs3211938. (Musunuru et al., 2012)  HDL and CRP levels are modestly 
correlated across these cohorts (e.g. Spearman’s correlation for ARIC= -0.050 and JHS= 
-0.037). Inclusion of HDL as a covariate in the linear models for the CARe samples only 
modestly impacted the association between CRP and rs3211938 (p = 1.4x10
-6
 for the 
model unadjusted for HDL vs. p =5.4x10
-6 
for the HDL-adjusted model), suggesting that 
the CD36 association with CRP levels is largely independent of HDL.  
We also found evidence at ARNTL, also termed BMAL1, which is a core 
component of the circadian clock and a vital element of the central circadian pacemaker. 
 48 
 
(Honma et al., 1998) This locus had suggestive evidence for association in the CHARGE 
report.  Molecular circadian clocks exist in peripheral tissues and coordinate gene 
transcription involved in a wide range of metabolic processes including gluconeogenesis, 
lipolysis, adipogenesis, and mitochondrial oxidative phosphorylation to achieve an 
appropriate internal alignment of metabolic signaling as well as external alignment of 
cellular processes. (Buijs et al., 2006)  It has been well documented that pathologic 
events display circadian rhythms with an increase in incidences, such as myocardial 
infarction and ischemia, from dawn to noon.(Maemura et al., 2001; Portman, 2001) 
Furthermore, experimental circadian misalignment is associated with abnormalities in 
blood pressure, glucose, and insulin levels (Scheer, Hilton, Mantzoros, & Shea, 2009) 
while shift work, a real-world model for circadian misalignment, is associated with 
diabetes and CVD.(Karlsson, Knutsson, & Lindahl, 2001; Knutsson, Akerstedt, Jonsson, 
& Orth-Gomer, 1986) Polymorphisms of ARNTL have been associated with age at 
menarche.  Inactivation of ARNTL results in altered regulation of blood pressure, lipid 
metabolism, and glucose homeostasis; and these changes have been observed in 
hypertensive mouse models.(Bunger et al., 2000; Curtis et al., 2007; Naito et al., 2003; 
Rudic et al., 2004; Shimba et al., 2005) The association between ARNTL and CRP 
suggests one possible mechanism of correlation between CRP and metabolic 
dysregulation, thereby increasing CVD risk.   
 Strengths of this study include the large African-American and European-ancestry 
dataset with measured CRP levels the large commercial candidate-gene-based genotyping 
panel. The generalizability to other populations remains to be determined. SNPs 
identified may not be causally linked to variation in CRP concentration levels, rather they 
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may be in linkage disequilibrium with the causal variants.  In addition, the functional 
mechanisms linking genetic variants to CRP concentrations remain to be determined.  
Finally, we had limited power to detect low frequency variants and SNPs with low effect 
size, especially in AAs.  We acknowledge that additional genomic loci may be uncovered 
in larger samples and with broader coverage of genetic variation across the human 
genome. 
 Our findings provide better insight about the pathways involved in variation in 
CRP concentrations and provide additional data implicating the role of circadian genes in 
influencing cardiovascular risk. Overall, these findings are consistent with the role of 
metabolism and inflammatory pathway in the regulation of circulating CRP levels. 
Materials and Methods 
 
Each study was reviewed by a local ethics board and all participants consented to genetic  
research. Genotype and phenotype data for all study participants, with the exception of 
KORA subjects, are available through the NCBI dbGaP resource 
(www.ncbi.nlm.nih.gov/gap).    
 
Study samples  
CARe 
The CARe (Candidate Gene Association Resource) consortium consists of nine studies.  
The purpose of the consortium was to bring together deeply-phenotyped prospective 
cohort studies to increase power for genetic association scans of CVD and other 
disorders. (Musunuru et al., 2012)  Cohorts included in these analyses of CRP levels are: 
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Atherosclerosis Risk in Communities (ARIC) (n=12,617), Coronary Artery Risk in 
Young Adults (CARDIA) (n=2,738), Cleveland Family Study (CFS) (n=1,349),  
the Cardiovascular Health Study (CHS) (n=4,704), Framingham Heart Study (FHS) 
(n=7,556), Jackson Heart Study (JHS) (n=2,036), and Multi-Ethnic Study of 
Atherosclerosis (MESA) (n=3,910). Further details of the participating CARe studies are 
reported in the Supplemental Methods. 
 
Women’s Health Initiative (WHI)  
WHI is one of the largest (n=161,808) studies of women's health ever undertaken in the 
U.S. ("Design of the Women's Health Initiative clinical trial and observational study. The 
Women's Health Initiative Study Group," 1998) There are two major components of 
WHI: (1) a Clinical Trial (CT) that enrolled and randomized 68,132 women ages 50 – 79 
years into at least one of three placebo-control clinical trials (hormone therapy, dietary 
modification, and calcium/vitamin D); and (2) an Observational Study (OS) that enrolled 
93,676 women of the same age range into a parallel prospective cohort study. ("Design of 
the Women's Health Initiative clinical trial and observational study. The Women's Health 
Initiative Study Group," 1998) A diverse population was recruited from 1993-1998 at 40 
clinical centers across the U.S.  
 
KORA  
The MONICA/KORA (MONItoring of trends and determinants in Cardiovascular 
disease/ Cooperative Health Research in the Region of Augsburg) Augsburg study is a 
series of population-based surveys conducted in the region of Augsburg in Southern 
Germany.(Lowel et al., 2005)  The data for the present study was drawn from a subcohort 
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randomly selected by sex and survey from surveys S1 to S2 conducted between 1984 and 
1990 (KORA S12) (Thorand et al., 2005) and from survey F3 conducted 2004/05 (KORA 
F3). After exclusion of subjects with no phenotype or IBC genotype data, with individual 
call rate < 0.90 and signs of relatedness (DST > 0.95), the study populations consisted of 
1,075 participants for KORA S12 and 1,800 participants for KORA F3. All participants 
were from European ancestry. 
 
Genotyping 
 
CARe 
The IBC SNP array is described in detail in Keating et al. (Keating et al., 2008) The IBC 
SNP array includes 49,320 SNPs selected across ~2,000 candidate loci for CVD. The 
array includes SNPs that capture patterns of genetic variation in both European- and 
African-descent populations.  Genotyping for the CARe cohorts was performed at the 
Broad Institute (Cambridge, MA). Criteria for DNA sample exclusion based on genotype 
data included sex mismatch, discordance among duplicate samples, or sample call rate 
<95%.  For each set of duplicates or monozygotic twins, data from the sample with the 
highest genotyping call rate were retained.  SNPs were excluded when monomorphic, the 
call rate was <95%, or when significant departures from expected Hardy-Weinberg 
equilibrium (HWE) genotype proportions were observed (p<10
–5
 in EAs).  Given the 
genetic admixture in African Americans, there was no HWE filter used for these samples.  
After these exclusions were applied, data remained on 47,539 SNPs.  
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Women’s Health Initiative 
DNA was extracted by the Specimen Processing Laboratory at the Fred Hutchinson 
Cancer research Center (FHCRC) using specimens that were collected at the time of 
enrollment. Only participants with CRP measured at baseline were included in this 
analysis. 
Genome-wide genotyping was performed at Affymetrix using the Affymetrix 6.0 
array.  A total of 8,421 AAs had genotype data that passed quality control.  A reference 
sample of 761 AA NHLBI Exome Sequencing Project (ESP) participants was used for 
imputation of CD36 rs3211938 into 8,041 AA WHI individuals with GWAS data using 
the programs MaCH 1.0.18 (Y. Li, Willer, Ding, Scheet, & Abecasis, 2010) and minimac 
(B.N. Howie, P. Donnelly, & J. Marchini, 2009) Additional details on the genotype 
imputation are given in Auer at al. (Auer, Srivastava, & Doerge, 2012) 
 
KORA 
Genotyping was done within the HumanCVD Genotyping Kit (IBC 50K Chip) as 
suggested by the manufacturer (Illumina, Inc., San Diego, USA). The genotyping was 
carried out using the CVD-Upenn_Phase1 manifest with the Beadstudio software 
(Genotyping module v.3.2.29, no call threshold 0.15). 
 
Data analysis 
Participants with CRP measurement over 10 mg/L were excluded from analysis as these 
observations would be highly influential and potentially a result of acute infection.  We 
natural log-transformed CRP level in order to generate an approximately normal 
distribution of model residuals, conditional on the covariates, to meet linear model 
assumptions.   
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We assumed an additive genetic model in all tests of association. We used the linear 
regression model implemented in PLINK (Purcell et al., 2007b) for studies with unrelated 
individuals and the linear mixed effects model implemented in the program GWAF for 
cohorts with related individuals (M.H. Chen & Q. Yang, 2010) to test for association 
between log-CRP and genotype at each SNP, adjusted for covariates.  All models were 
stratified by cohort and race. Covariate adjustment was applied for age, sex, current 
smoking, body mass index and the first 10 principal components calculated using the 
program EIGENSTRAT (A.L. Price et al., 2006) to control for potential population 
substructure. After obtaining cohort- and race-specific results, we performed a fixed-
effects, inverse variance-weighted meta-analysis using the METAL software.(C.J. Willer, 
Y. Li, & G.R. Abecasis, 2010) Meta-analysis was performed separately by race and race-
combined. 
 Based on a simulation analysis performed by Lettre and colleagues, the effective 
number of independent tests was calculated to be 26,482 for the African Americans and 
20,544 for samples of primarily European ancestry, accounting for the linkage 
disequilibrium between markers on the IBC array.  To maintain an overall type 1 error 
rate of 5%, a uniform statistical threshold of α = 2.2 x 10-6 (0.05/25000) was thus used to 
declare array-wide (experiment-wide) significance.(Nalls et al., 2011)  
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Table 2.1. Study sample characteristics (% or mean±SD)  
 ARIC CARDIA CFS CHS FHS JHS MESA WHI KORA 
 EA AA EA AA EA AA EA AA EA AA EA AA EA EU 
N 7581 1987 1332 1126 281 371 3919 736 7556 2026 2051 1338 4389 2866 
Female, % 53.9 64.1 53.2 59.2 53.0 58.0 56.3 62.5 53.8 60.6 52.0 53.7 100.0 48.9 
Current Smoker, % 20.9 26.1 23.0 29.3 24.6 18.3 11.1 16.1 50.0 15.1 10.7 17.9 7.6 21.8 
Diabetes, % 7.6 16.5 0.53 0.85 11.1 17.6 14.7 24.6 10.9 15.4 5.8 16.2 7.3 4.5 
Age, y 54.1 
±5.7 
52.9 
±5.7 
25.7 
±3.3 
24.4 
±3.8 
44.3 
±19.3 
40.4 
±18.6 
72.8 
±5.6 
73.0 
±5.7 
48.8 
±13.7 
50.0 
±12.0 
62.2 
±10.1 
61.7 
±9.8 
68.2 
± 6.5 
52.1 
±10.7 
Body Mass 
Index, kg/m2 
26.9 
±4.7 
29.6 
±5.9 
23.7 
±4.0 
25.6 
±5.7 
31.7 
±9.2 
33.1 
±9.8 
26.4 
±4.5 
28.5 
±5.6 
27.4 
±5.5 
32.2 
±7.8 
27.7 
±5.1 
30.1 
±5.7 
27.6 
± 6.8 
27.2 
±4.1 
CRP, mg/L 4.02 
±5.6 
5.8 
±7.1 
2.4 
±3.7 
4.3 
±6.3 
3.8 
±5.2 
4.6 
±6.2 
4.3 
±6.7 
6.1 
±8.2 
3.3 
±6.2 
5.1 
±7.7 
3.4 
±5.1 
4.7 
±6.9 
4.2 
± 6.1 
2.8 
±5.2 
EA=European American; AA=African American; EU=European 
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Table 2.2: Loci associated with CRP in the African American samples 
 
Chr. No. SNPs 
P<2.2x10
-
6 
Most 
Significant 
Position Allele Freq.* Beta(SE)* het p-
value 
p-value Gene 
1q23 13 rs3093058 157951939 T/A 0.17 0.39(0.022) 0.69 4.2x10
-71
 CRP 
1q21 2 rs8192284 152693594 A/C 0.14 -0.12(0.025) 0.60 2.0x10
-6
 IL6R 
7q21 1 rs3211938 80138385 T/G 0.08 -0.14(0.030) 0.22 1.6x10
-6 
CD36 
19q13 2 rs769450 50102284 G/A 0.37 0.083(0.017) 0.16 1.6x10
-6 
TOMM40 
* Allele frequency and beta estimate is presented for second allele. 
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Table 2.3. Loci associated with CRP in a meta-analysis of African Americans (AA) and subjects of European (Eur) descent. 
 
Chr. Most 
Significant 
Alleles Position Freq. 
(Eur)* 
Beta(SE) 
(Eur)* 
p-value 
(Eur) 
Freq. 
(AA)* 
Beta(SE) 
(AA)* 
p-value 
(AA) 
Meta-
analysis 
p-value 
Gene 
1p31 rs1805096 G/A 65874845 0.38 -0.098(0.009) 3.3x10
-30 
0.45 -0.061(0.017) 2.5x10
-4 
2.6x10
-32 
LEPR 
1q21 rs4129267 C/T 152692888 0.40 -0.079(0.008) 5.2x10
-21 
0.13 -0.12(0.025) 5.7x10
-7 1.2x10
-24 
IL6R 
1q23 rs3091244 A/G 157951289 0.62 -0.17(0.009) 3.5x10
-91 
0.45 -0.24(0.017) 5.1x10
-45 
7.8x10
-132 
CRP 
1q44 rs12239046 C/T 245668218 0.39 -0.039(0.009) 5.3x10
-6 
0.51 -0.064(0.017) 1.4x10
-4 
7.3x10
-9 
NLRP3 
2p23 rs1260326 C/T 27584444 0.43 0.094(0.008) 5.3x10
-29 
0.14 0.056(0.024) 0.019 1.0x10
-29 
GCKR 
2q13 rs4251961 T/C 113590938 0.38 0.060(0.009) 1.4x10
-12 
0.18 0.081(0.022) 2.0x10
-4 
1.8x10
-15 
IL1RN 
7q11 rs714052 A/G 72502805 0.12 -0.065(0.013) 3.9x10
-7 
0.042 -0.056(0.044) 0.20 1.7x10
-7 
BAZ1B 
7q21 rs3211938 T/G 80138385 <0.001 -0.42(0.54) 0.44 0.085 -0.14(0.030) 1.6x10
-6 
1.4x10
-6 
CD36 
11p15 rs6486121 T/C 13312606 0.37 -0.043(0.009) 6.4x10
-7 
0.58 -0.037(0.017) 0.026 1.3x10
-7 
ARNTL 
12q24 rs2244608 A/G 119901371 0.34 -0.11(0.009) 4.6x10
-39 
0.14 -0.076(0.024) 0.0016 9.5x10
-41 
HNF1A 
17q23 rs1292034 G/A 55344642 0.45 -0.037(0.008) 6.0x10
-6 
0.82 -0.039(0.02) 0.079 1.2x10
-6 
RPS6KB1 
19q13 rs2075650 A/G 50087459 0.13 -0.18(0.012) 2.2x10
-47 
0.13 0.039(0.02) 0.11 1.9x10
-34 
TOMM40 
20q13 rs1800961 C/T 42475778 0.030 -0.13(0.024) 2.0x10
-7 
0.0070 -0.14(0.10) 0.18 7.8x10
-8 
HNF4A 
* Allele frequencies and beta estimates are presented for second allele. 
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Table 2.4. Loci associated with CRP in the independent European American replication sample (CARDIA,CFS, MESA, WHI) 
 
 
Allele frequency and beta estimate is presented for second allele. 
 
Chr. No. SNPs 
P<2.2x10
-6 
Most 
Significant 
Position Allele Freq.* Beta(SE)* het p-value p-value Gene 
1p31 19 rs1805096 65874845 G/A 0.38 -0.14(0.017) 0.61 2.5x10
-18 
LEPR 
1q21 5 rs4129267 152692888 C/T 0.40 -0.10(0.016) 0.69 6.1x10
-10 
IL6R 
1q23 9 rs3091244 157951289 G/A 0.38 0.18(0.016) 0.61 2.9x10
-28 
CRP 
2p23 3 rs1260326 27584444 C/T 0.43 0.085(0.016) 0.35 1.5x10
-7 
GCKR 
12q24 5 rs2244608 119919810 A/G 0.31 -0.12(0.017) 0.38 1.2x10
-14 
HNF1A 
19q13 6 rs12721046 50087459 G/A 0.13 0.18(0.023) 0.36 7.3x10
-15 
APOC1 
  
 
 
 
 
 
CHAPTER 3 
ASSESSMENT OF SMOKING EFFECTS ON GSTM1 AND GSTT1 GENOTYPE 
EFFECTS AND C-REACTIVE PROTEIN LEVELS 
 
Glutathione S-transferases (GSTs) are a family of Phase II enzymes that are 
responsible for the metabolic inactivation of electrophilic compounds and toxic substrates 
(Conklin et al., 2009), (Tirona & Pang, 1999; Townsend, Findlay, & Tew, 2005; Wu, 
Fang, Yang, Lupton, & Turner, 2004). GSTs are divided into three main families: 
cytosolic, mitochondrial, and membrane-bound.  The cytosolic family is further divided 
into seven classes which include the mu and theta classes encoded by the genes GSTM1 
and GSTT,1 respectively.  Many epidemiological studies have focused on these two gene 
classes because these isoforms are polymorphically deleted (Board, 1981) and likely to 
contribute to inter-individual differences in response to xenobiotics and clearance of 
oxidative stress products (J. Wang et al., 2010).  Thus, it has been suggested that these 
variations may determine susceptibility to various inflammatory pathologies including 
cardiovascular disease (CVD).  Furthermore, studies have also suggested that these GST 
variations may alter CVD risk to a greater extent in cigarette smokers than non-smokers 
(Conklin & Bhatnagar, 2011).   
Cigarette smoking is a common habit that affects about 23% of the adult US 
population (Jockel et al., 2009) being causally linked to myocardial infarction, stroke, 
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coronary artery disease and other forms of CVD (Yusuf et al., 2004). Because evidence 
has shown cigarette smoking to be associated with systemic inflammation, it has been 
hypothesized that inflammation may be one of the mechanisms through which smoking 
affects CVD (Unverdorben et al., 2009).   
Increased levels of C-reactive protein (CRP), a pentameric acute-phase protein, is a 
trademark of low-grade systemic inflammation (P. M. Ridker & Silvertown, 2008) and a 
biomarker used in CVD risk prediction.  The association between CRP and smoking has 
been established by many epidemiological studies. (Asthana et al., 2010; Benowitz, 2003; 
Burns, 2003; Danesh et al., 2004b)  Increased CRP levels were found in former and 
current smokers (Lowe, Yarnell, Rumley, Bainton, & Sweetnam, 2001), and only those 
former smokers who had quit for more than 20 years had CRP levels comparable to their 
never smoking counterparts (Wannamethee et al., 2005).  It has been well demonstrated 
that circulating levels of CRP are influenced by smoking (Z. Chen & Boreham, 2002) and 
genetic factors (Danesh et al., 2004b; Pepys & Hirschfield, 2003; R. P. Tracy et al., 
1997); however, it is not yet clear how smoking influences genetic effects on CRP levels.         
  Candidate genes studies have explored whether smoking effect on CRP is 
modified by genetic variation.  The glutathione-S-transferases (GSTs) have been one of 
the primary classes of genes evaluated because they are involved in the detoxification 
and/or activation of some chemicals in cigarette smoke (Ambrose & Barua, 2004; Brook 
et al., 2010). 
The Atherosclerosis Risk in Communities (ARIC) study looked at null and 
functional genotypes in GSTM1 and GSTT1 in 989 African and European American 
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participants.  Participants who smoked ≥ 20 pack-years and carried the null GSTT1 
genotype had the highest mean levels of CRP, but the smoking interaction term did not 
reach statistical significance (Miller et al., 2003).  The STANISLAS group conducted a 
similar study using a sample of 265 French individuals.  
This group identified smoking interactions between CRP, white blood cell (WBC) count, 
and TNFα and GSTM1 genotypes (p<0.05); however, they did not observe any significant 
interactions between smoking and GSTT1 genotypes for any of the biomarkers measured 
(Habdous, Siest, Herbeth, Vincent-Viry, & Visvikis, 2004).  The relatively limited 
sample sizes in these studies likely limited power to detect significant interactions. 
We sought to assess whether the effect of smoking pack years on CRP is modified 
by genetic polymorphisms in GSTM1 and GSTT1 using a large multi-ethnic consortium 
of both European-American and African-American participants.  Participants came from 
community-based cohorts from the Candidate Gene and Association Resource (CARe) 
consortium with genotype data from the ITMAT Broad-CARe (IBC) Chip, a custom 
50,000 SNP gene-centric array having dense coverage of over 2,000 candidate genes for 
CVD pathways. 
Results 
 
Characteristics of the 20,874 EA and 6,489 AA study participants can be found in 
Table 3.1. Smoking prevalence was higher in European Americans, whereas CRP levels 
and BMI were higher in African Americans.  Allele frequencies, by race, for all variants 
tested can be found in Table 3.2.  Large allele-frequency differences were observed for 
several of the polymorphisms in GSTT1 and GSTM1 between EAs and AAs. 
 61 
 
Nominal evidence for a main-effect association between log-CRP and GSTT1 
variant rs405597 (p=0.014) was observed in EAs; no other variants in GSTM1 or GSTT1 
were associated with log-CRP (Table 3.3). A significant interaction between rs405597 
and log pack-years (p=0.002) on log CRP was observed in EAs. No other significant 
interactions were observed in either EAs (Table 3.4) or AAs (Table 3.5). To further 
understand the interaction between log pack-years and rs405597 genotype on CRP, we 
performed stratified association analysis, by genotype, ethnicity and cohort (Table 3.6) 
with log-pack-years as the primary predictor. Among EAs, there was a consistent trend, 
across cohorts, of a stronger positive relationship between log-pack-years and log-CRP 
levels for homozygotes carrying the common allele, in relative comparison to the other 
genotype groups. For the most part, with exception to ARIC, we observed a consistent 
trend supporting an additive interaction between genotype and log pack-years on log-
CRP in EAs. Consistent with the lack of evidence for an interaction in AAs, we saw no 
evidence for consistent trends regarding the effects of smoking on CRP between cohorts 
or genotype categories in this population. 
To further explore the GSTT1 gene variants, we performed a haplotype analysis in 
both our European and African American cohorts. These SNPs define seven haplotypes 
in EAs and six haplotypes in AAs (freq ≥ 0.02).  Haplotype analysis in EAs confirmed 
that rs405597 tags a haplotype associated with elevated CRP levels after adjustment for 
age, gender, log pack-years, and 10 principal components (p=0.04).  Haplotype analysis 
in AAs for the same haplotype or any other identified haplotypes showed no association 
(p=0.75).  
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Discussion 
 
 It has been a long-standing hypothesis that mechanisms of detoxification regulate 
disease susceptibility in cancer research; however, this concept has only recently begun 
to surface in the field of cardiovascular disease (Conklin & Bhatnagar, 2011). The 
mechanisms linking detoxification and CVD remain largely unknown except in the case 
of GSTs (Hayes, Flanagan, & Jowsey, 2005).   
Glutathione is a tripeptide composed of glutamine, cysteine, and glycine. The 
thiol group is a potent reducing agent making it the most abundant intracellular small 
molecule. Glutathione is an important antioxidant as it plays a primary role in the 
detoxification of a variety of electrophilic compounds and peroxides via the catalysis of 
GSTs (Anderson, 1998; Mullineaux et al., 1998).  GSTs are multifunctional proteins, 
meaning in one environment they could protect against disease by removing harmful 
toxins yet in a different environment they could attenuate the effects of beneficial 
substances (Conklin & Bhatnagar, 2011). Although there are many classes of GSTs, to 
our knowledge, the only ones that may contribute to variations in pathology or clinical 
response are the mu and theta classes (C. M. Smith et al., 1994; Strange et al., 2000).   
Several studies have explored the interaction between smoking and the mu and 
theta classes of GSTs in relation to CVD outcomes.  One study assessed the effects of 
smoking with GSTT1 and GSTM1 null genotypes in a case-cohort coronary artery disease 
(CAD) study.  Subjects who were current smokers and carried the GSTM1 null genotype 
had a 1.63-fold higher relative risk of CAD, and those smokers who carried the GSTT1 
null genotype had a 2.6-fold higher relative risk (Tamer et al., 2004).  Another study 
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assessed parental effects of cigarette exposure.  Cresci, et al. investigated the effect of 
maternal and paternal cigarette exposure in children who did not produce GSTM1 and 
GSTT1 enzymes in relation to congenital heart disease risk (Cresci et al., 2011).  A 
significant interaction was observed between GST genotypes and parental exposure to 
cigarette smoke; children with null GST genotypes had a greater risk than children with 
functional genotypes when both parents were exposed to cigarette smoke.  The ARIC 
study investigated the role of GSTT1 and GSTM1 genotypes modifying the effect of 
smoking on subclinical CVD events.  They observed that smokers with a history of 20 or 
more pack years who carried GSTT1 coding-region deletions had increased odds, 
compared with never smokers and smokers with less than 20 pack years, of having 
preclinical atherosclerosis, which was measured by carotid IMT (intima-medial 
thickness) (Olshan et al., 2003).    
While previous reports have studied the relationships between polymorphisms in 
GSTM1 and GSTT1 , nicotine exposure and disease risk (Hayes & Strange, 2000)(10-Du 
201), no large study has characterized these relationships using common genetic variants 
(Moyer et al., 2007). The most commonly studied form of GSTM1 and GSTT1 variants 
have been deletion polymorphisms, which have been shown to cause a reduction in GST 
expression and the inability to detoxify xenobiotics and carcinogens (Townsend et al., 
2003).  The prevalence of null (or deletion) genotypes has been reported to be highest  
among Chinese and Koreans and lowest among Mexican Americans (Nelson et al., 
1995).  In the ARIC cohort, included among our cohorts, the prevalence of GSTT1 
deletion polymorphisms is higher among African Americans (~33%) compared to  
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European Americans and the prevalence of GSTM1 deletion polymorphisms is higher 
among European Americans (~50%) compared to African Americans (Miller et al., 
2003). 
Oxidative stress plays a major role in the pathogenesis of atherosclerosis, a 
primary risk factor of CVD, and GSTs detoxify metabolites produced by oxidative stress 
protecting the cell against injury (Doney, Lee, Leese, Morris, & Palmer, 2005; 
Turkanoglu, Can Demirdogen, Demirkaya, Bek, & Adali, 2010).  It has been shown that 
when GST enzymatic activity is inhibited, oxidative-stress induced apoptosis is 
exacerbated (Roth et al., 2011).  GSTT1 deletion polymorphisms are linked to 
cardiovascular diseases because they reduce levels of cellular detoxification  due to 
minimal or no GST expression (Ntais, Polycarpou, & Ioannidis, 2005; Raimondi et al., 
2006; White, Li, Nurgalieva, & El-Serag, 2008; Ye, Song, Higgins, Pharoah, & Danesh, 
2006).  We identified five transcription sites via the TRANSFAC (a transcription factor 
database) (Wingender et al., 2000) that rs405597 could be altering suggesting its role in 
GSTT1 gene expression. Therefore, exposure to nicotine may cause a decrease in GST 
expression thus reducing glutathione conjugation of electrophilic compounds and 
peroxides.  Consequently, reduction in conjugation results in increased levels of reactive 
oxygen species (ROS) and the oxidation of lipids in the endothelium (Townsend et al., 
2005).   
We identified one GSTT1 polymorphism (rs405597) that showed both nominally 
significant evidence for a main-effect association and significant evidence for an 
interaction with smoking on CRP in EAs. Rs405597 is in modest linkage disequilibrium  
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(LD) with a GSTT1 deletion (D’=0.29) in CEUs and in strong LD (D’=0.99) in Yorubans 
(YRI) (Zhao, Marotta, Eichler, Eng, & Tanaka, 2009).  It is unclear whether the observed 
associations with GSTT1 rs405597 are due to LD with the deletion.  Interestingly, we 
note that we saw no evidence for either main effects or interaction effects with rs405597 
in AAs even though this variant is in stronger LD with the deletion in this population. 
The major strength of this study is the large sample size of both European and 
African Americans with measured CRP, smoking exposure data and GSTT1 and GSTM1 
genotype data.  Generalization to other populations remains to be determined and the 
functional mechanisms linking genetic variants in the genes to CRP concentrations under 
nicotine exposure are also unknown, as the SNPs studied may not be causally linked to 
variation in CRP concentration levels but rather be in linkage disequilibrium with the 
causal variants.  We only had a limited number of GSTM1 and GSTT1 SNPs for study 
and it is conceivable that we missed important effects with other variants that could have 
been detected with broader SNP coverage, including uncommon variants, in and around 
these genes. Perhaps most importantly, our study was unable to include data on the 
deletions in these genes that have been previously studied, limiting our ability to draw 
direct inference into whether our observed interaction between GSTT1 rs405597 and 
pack-years reflected linkage disequilibrium with previously studied null variants.  
Lastly, we recognize that the use of pack-years as a smoking variable does present 
potential drawbacks in our analysis. Pack-years is a widely use smoking index in most 
epidemiological studies because it combines the duration of smoking and smoking 
magnitude (Hellenbrand et al., 1997; Uchimoto et al., 1999).  
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However, this index makes the assumption that the dose of smoking one cigarette per day 
for 10 years is equivalent to smoking 10 cigarettes per day for one year (Doll & Peto, 
1978).  For the hazard of smoking related diseases such as lung disease, duration of 
smoking appears to have a greater effect than the number of cigarettes smoked per day 
(Doll & Peto, 1978).  In contrast, in the case of heart disease, smoking intensity appears 
to have a greater role in disease risk.  Disease risk decreases rapidly after initial smoking 
cessation, but the rate of decreased risk slows down after the first year of cessation 
(Landmark, 2001). In a recent study that assessed the relationship between four measures 
of smoking intensity (pack-years, cigarettes/day, the Fagerstrom Test of Nicotine 
Dependence, and exhaled carbon monoxide levels) and CRP levels, correlations were 
only observed for pack-years as a smoking index, albeit the correlation was modest 
(r=0.05) (Asthana et al., 2010).  The assessment of inflammatory markers such as CRP, it 
is unclear whether measures of both smoking cessation and duration should be considered 
(Wannamethee et al., 2005). Finally, strong correlations between CRP and adiposity may 
mask the effects of smoking on CRP (Asthana et al., 2010). We chose to include BMI as 
a covariate in our models to partially address any possible confounding between 
smoking, genotype and smoking on CRP levels.  Higher order interaction models 
including BMI would be of interest, though sample size constraints would likely severely 
limit power even for our relatively large study.  
 Our findings illustrate the importance of studying the interaction between genes 
and environmental exposures on subclinical measures of CVD. Specifically, our results 
provide supporting evidence regarding the interaction between GSTT1 genotypes and 
smoking behavior on CRP. Our results could provide better insight about the pathways 
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involved in CVD initiation and progression.  Moreover, these findings also illustrate the 
need to create better smoking indices to measure the effects of gene-by-environment 
interactions.  It also alludes to the need to characterize more variants within the GST 
classes so that we can better interrogate these genes, ultimately determining the 
functionally important variants, to better understand their relationship to cardiovascular 
disease risk. 
 
Materials and Methods 
 
CARe 
The CARe (Candidate Gene Association Resource) consortium consists of nine 
studies.  The purpose of the consortium was to bring together deeply phenotyped 
prospective cohort studies to increase power for genetic association scans of CVD and 
other disorders (Musunuru et al., 2012).  Cohorts included in this smoking interaction 
with CRP levels were Atherosclerosis Risk in Communities (ARIC), the Cardiovascular 
Health Study (CHS), the Framingham Heart Study (FHS), and the Multi-Ethnic Study of 
Atherosclerosis (MESA). Further details of the participating CARe studies are reported in 
the Supplemental Methods. 
 
Genotyping 
CARe 
The IBC SNP array is described in detail in Keating et al. (Keating et al., 2008).  The IBC 
SNP array includes 49,320 SNPs selected across ~2,000 candidate loci for CVD.  
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The array includes SNPs that capture patterns of genetic variation in both European- and 
African-descent populations.  Genotyping for the CARe cohorts was performed at the 
Broad Institute (Cambridge, MA). Criteria for DNA sample exclusion based on genotype 
data included sex mismatch, discordance among duplicate samples, or sample call rate 
<95%.   
For each set of duplicates or monozygotic twins, data from the sample with the highest 
genotyping call rate were retained.  SNPs were excluded when monomorphic, the call 
rate was <95%, or HWE was p<10
–5
 in EAs.  Given the genetic admixture in African 
Americans, there was no HWE filter used for these samples.   
 
Data analysis 
Participants with CRP measurements over 10 mg/L were excluded from analysis as these 
observations would be highly influential and potentially a result of acute infection.  We 
natural log-transformed CRP level to generate an approximately normal distribution of 
model residuals, conditional on the covariates, to meet linear model assumptions.  We 
assumed an additive genetic model in all tests of association and modeled log-
transformed pack-years to assess the impact of smoking.  Main-effect (between log-CRP 
and genotype, with smoking as a covariate) and interaction-effect (modeling interaction 
between genotype and smoking on log-CRP) association analyses were performed using 
linear regression models implemented in PLINK (Purcell et al., 2007a) for cohorts with 
unrelated individuals and linear mixed models implemented in GWAF for cohorts with 
related individuals (M. H. Chen & Q. Yang, 2010). All models were stratified by cohort 
and race.   
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We adjusted for age, sex,  body mass index (BMI), LDL-C, HDL-C, and the first 10 
principal components calculated using the program EIGENSTRAT (A. L. Price et al., 
2006) to control for potential population substructure.  After obtaining cohort-specific 
results, we performed fixed-effects, inverse variance-weighted meta-analyses, separately 
by race, using the METAL software (C. J. Willer, Y. Li, & G. R. Abecasis, 2010).   
A statistical threshold of α = 0.0045 (0.05/11) was thus used to declare significance. 
Finally, we performed selected haplotype-based association analyses around interesting 
variants using the haplo.stats package for R (Lake et al., 2003).  
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Table 3.1. Participant characteristics by cohort/ethnicity  
 
 
 
 ARIC CHS FHS JHS MESA 
 EA AA EA AA EA AA EA AA 
N 8574 2600 3766 692 6472 1864 2035 1333 
Female, % 53.9 64.1 56.3 62.5 53.8 60.6 52.0 53.7 
Pack-years 15.04±22.94 8.59±19.52 18.63±27.3 13.76±23.8 7.73±16.83 29.6±28.6 14.37±27.4 11.42±18.7 
Age, y 54.1±5.7 52.9±5.7 72.8±5.6 73.0±5.7 48.8±13.7 50.0±12.0 62.2±10.1 61.7±9.8 
Body Mass 
Index, kg/m2 
26.9±4.7 29.6±5.9 26.4±4.5 28.5±5.6 27.4±5.5 32.2±7.8 27.7±5.1 30.1±5.7 
CRP, mg/L 4.02±5.6 5.8±7.1 4.3±6.7 6.1±8.2 3.3±6.2 5.1±7.7 3.4±5.1 4.7±6.9 
LDL, mg/dL 137.8±37.8 138.3±43.3 129.9±35.6 129.2±36.6 139.7±38.0 126.4±37.
1 
117.1±30.1 116.8±32.6 
HDL, mg/dL 50.5±16.7 54.8±17.4 53.5±15.7 57.9±15.5 54.1±16.5 51.6±14.8 52.5±15.8 52.4±15.1 
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Table 3.2.  Allelic frequencies of GSTM1 and GSTT1 polymorphisms in European and African Americans 
    European Americans African Americans 
Chromosome SNP Gene Location Major Minor MAF Major Minor MAF 
22 rs405597 GSTT1 22734578 A C 0.06 A C 0.11 
22 rs422674 GSTT1 22736778 C A 0.36 C A 0.07 
22 rs738809 GSTT1 22735492 A G 0.28 A G 0.30 
22 rs11090305 GSTT1 22737483 T C 0.19 T C 0.40 
1 rs574344 GSTM1 110015037 T A 0.08 T A 0.10 
1 rs655315 GSTM1 110016701 A G 0.49 A G 0.19 
1 rs12024479 GSTM1 110021609 C G 0.48 C G 0.28 
1 rs7537275 GSTM1 110022262 T A 0.001 T A 0.13 
1 rs412543 GSTM1 110031467 C G 0.04 C G 0.14 
1 rs7553593 GSTM1 110048621 G A 0.0004 G A 0.02 
1 rs10857797 GSTM1 10050887 T G 0.02 T G 0.37 
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Table 3.3. Main effects for polymorphisms in GSTM1 and GSTT1 in European Americans and African Americans for C-reactive 
protein 
  European Americans African Americans 
SNP Gene Beta Se P-value Beta Se P-value 
rs405597 GSTT1 -0.052 0.021 0.014 -0.031 0.031 0.319 
rs422674 GSTT1 0.005 0.011 0.643 0.004 0.038 0.918 
rs738809 GSTT1 0.009 0.011 0.434 -0.008 0.021 0.692 
rs11090305 GSTT1 -0.007 0.013 0.616 -0.008 0.020 0673 
rs574344 GSTM1 -0.026 0.018 0.163 0.082 0.033 0.012 
rs655315 GSTM1 -0.005 0.010 0.653 0.026 0.025 0.290 
rs12024479 GSTM1 -0.005 0.010 0.628 0.014 0.022 0.514 
rs7537275 GSTM1 0.042 0.161 0.796 -0.020 0.029 0.488 
rs412543 GSTM1 0.061 0.025 0.015 -0.059 0.060 0.327 
rs7553593 GSTM1 -0.04 0.232 0.919 -0.005 0.061 0.929 
rs10857797 GSTM1 -0.0007 0.035 0.984 -0.002 0.026 0.951 
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Table 3.4. Interaction effects with log-pack years for polymorphisms in GSTM1 and GSTT1 in European Americans  
SNP Gene Main effect 
Beta 
Main effect    
SE 
Interaction 
Beta 
Interaction  
SE 
Interaction  
Pvalue 
rs405597 GSTT1 -0.107 0.027 0.041 0.013 0.002 
rs422674 GSTT1 0.004 0.014 0.001 0.007 0.889 
rs738809 GSTT1 0.004 0.015 0.002 0.007 0.802 
rs11090305 GSTT1 -0.0101 0.017 0.002 0.008 0.802 
rs574344 GSTM1 -0.032 0.024 0.005 0.011 0.639 
rs655315 GSTM1 -0.0006 0.013 -0.0003 0.006 0.960 
rs12024479 GSTM1 -0.016 0.013 0.006 0.006 0.339 
rs7537275 GSTM1 0.060 0.202 -0.042 0.099 0.674 
rs412543 GSTM1 0.069 0.033 -0.005 0.015 0.761 
rs7553593 GSTM1 -0.165 0.273 -0.098 0.201 0.625 
rs10857797 GSTM1 0.005 0.047 -0.006 0.021 0.765 
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Table 3.5. Interaction effects with log-pack years for polymorphisms in GSTM1 and GSTT1 in African Americans  
SNP Gene Main Effect 
Beta 
Main Effect 
SE 
Interaction 
Beta 
Interaction 
SE 
Interaction 
Pvalue 
rs405597 GSTT1 -0.024 0.039 -0.006 0.021 0.777 
rs422674 GSTT1 -0.002 0.048 0.005 0.024 0.838 
rs738809 GSTT1 -0.009 0.026 0.002 0.014 0.873 
rs11090305 GSTT1 -0.002 0.025 -0.009 0.013 0.500 
rs5760176 GSTT1 0.028 0.034 -0.016 0.017 0.366 
rs574344 GSTM1 0.056 0.041 0.021 0.022 0.327 
rs655315 GSTM1 -0.01 0.031 0.031 0.016 0.049 
rs12024479 GSTM1 0.010 0.028 0.001 0.014 0.920 
rs7537275 GSTM1 -0.059 0.037 0.032 0.019 0.094 
rs412543 GSTM1 -0.103 0.077 0.035 0.039 0.370 
rs7553593 GSTM1 0.082 0.078 -0.077 0.042 0.067 
rs10857797 GSTM1 0.021 0.032 -0.019 0.017 0.278 
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Table 3.6. Main effects for association with log-pack years and C-reactive protein by genotype for rs405597 
 rs405597_AA rs405597_AC rs405597_CC 
European Americans Beta(SE) P-value Beta(SE) P-value Beta(SE) P-value 
ARIC  0.092(0.008) 2.1x10
-32 
0.028(0.021) 0.194 0.038(0.148) 0.015 
CHS  0.072(0.009) 1.5x10
-14 
0.032(0.028) 0.254 -0.040(0.218) 0.858 
FHS  0.144(0.010) 4.8x10
-35 
0.119(0.031) 1.5x10
-4 
n/a n/a 
MESA  0.050(0.014) 2.1x10
-4 
-0.051(0.041) 0.217 -0.119(0.244) 0.646 
African Americans       
ARIC  0.107(0.020) 6.3x10
-8 
0.061(0.040) 0.132 0.388(0.196) 0.069 
CHS 0.082(0.026) 0.002 0.071(0.062) 0.253 0.329(0.315) 0.406 
JHS 0.078(0.020) 9.9x10
-5 
0.081(0.044) 0.067 0.003(0.207) 0.989 
MESA 0.061(0.020) 0.002 0.135(0.040) 8.8x10
-4 
0.380(0.198) 0.151 
 
  
 
 
 
 
 
CHAPTER 4 
GENOME-WIDE ASSOCIATION STUDY OF AFRICAN AMERICANS AND 
HOMOCYSTEINE LEVELS 
 
 Cardiovascular disease (CVD) is the leading cause of death globally; 1 in 4 deaths 
in the US are caused by CVD. African Americans (AAs) have the highest rates of CVD 
and CVD mortality in the US; approximately 46% of AAs have been diagnosed with 
CVD (Henry et al., 2012).  Plasma homocysteine (Hcy) is an established marker for CVD 
and elevated Hcy concentrations are associated with venous thrombosis, coronary heart 
disease, stroke, and atherosclerosis (Cattaneo, 1999; Homocysteine Studies, 2002; Wald 
et al., 2002; Welch & Loscalzo, 1998).  Because it is influenced by multiple 
environmental factors (Brattstrom et al., 1994), its role in CVD is interesting and 
complex.  Age, gender, renal function, vitamin intake, cigarette smoking, and menopause 
are among the main environmental determinants of Hcy levels (Brattstrom et al., 1994). 
Hcy also has an important genetic component, as heritability is estimated to be 47%-70% 
(Lange et al., 2010) and genetic mutations in enzymes for Hcy metabolism have long 
been known to be associated with Hcy level. There are at least two functional variants 
(677C>T and 1298A>C) in the gene for methylenetetrahydrofolate reductase (MTHFR), 
which catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate, the primary circulating form of folate (Brustolin, Giugliani, & 
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Felix, 2010).  Mutations in the gene for cystathione-β-synthase (CBS), which catalyzes 
the transsulfuration converting Hcy to cystathionine, which in turn is converted to 
cysteine, is known to markedly increase Hcy level and leads to increased rates of 
premature stroke and venous thrombosis (Selhub, 1999).  
Genome-wide association (GWA) studies have been conducted for Hcy, but these 
have so far been limited to populations of European ancestry (Hazra et al., 2009; 
Malarstig et al., 2009; Pare et al., 2009; Tanaka et al., 2009) and Filipinos (Lange et al., 
2010). All of these GWA studies observed evidence for association with Hcy for 
common variants in the MTHFR and CBS loci. A GWA study in 13,974 EA women from 
the Women’s Genome Health Study (WGHS) identified and replicated two novel loci for 
Hcy: DPEP1 and CPS1, although CPS1 was replicated only in women in the 
confirmatory sample.  The CPS1 locus was also found to be associated with Hcy in a 
GWA study of 1786 Filipino women and additional analysis in the adult offspring of the 
original sample confirmed that the association is only in women. Evidence for 
modification of genotype effects by sex has also been seen for MTHFR, where the effect 
magnitude of the 677C>T polymorphism is stronger in males than females (Lange et al., 
2010; Pare et al., 2009).   
While no GWA studies for Hcy in samples of African ancestry have been 
reported to date, candidate gene studies have been conducted in AA samples. The 
Coronary Artery Risk Development in Young Adults (CARDIA) performed a candidate 
gene study to assess the associations between variants in MTHFR, CBS and two  
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additional genes for Hcy enzymes before and after folic acid fortification, which was 
mandated by the US Food and Drug Administration in 1996.  Significant associations 
were detected in both European and AAs pre-folic acid fortification era at all loci; 
however, post-folic era, no associations at the MTHFR variants were detected in AAs 
(Tsai et al., 2009).   
A study about thhe clinical utility of the MTHFR 677 C>T variant reported that the 
prevalence of homozygote (TT) genotypes were much smaller in AAs versus EAs (<1% 
compared to 12% respectively) (Tsai et al., 2009). In an analysis of MTHFR 
polymorphisms conducted in the WGHS, no associations between either of the known 
MTHFR SNPs (677C>T and 455G>A) and Hcy were observed in AA women (Albert et 
al., 2009). Additionally, the prevalence of MTHFR genotypes was lowest in AA women 
(~4 %) in a study that assessed the heterogeneity of MTHFR polymorphisms in women 
from four different ethnic backgrounds (Esfahani et al., 2003).   
 Herein, we performed a genome-wide association meta-analysis of AA samples 
from three cohorts to identify loci associated with Hcy concentration. Study participants 
came from CARDIA, the Jackson Heart Study (JHS), and the Multi-Ethnic Study of 
Atherosclerosis (MESA). 
Results 
Characteristics of the 3,817 African American study participants are presented in 
Table 1. Consistent with prior reports, Hcy levels are higher in men.  A higher proportion 
of men currently smoke while women have, on average, higher BMI.   
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The Manhattan plot for men is shown in Figure 1a and the Quantile-Quantile 
(QQ) plot is shown in Figure 4.2a.  In men, we observed genome-wide significant 
evidence for an association with Hcy at chromosome 8 SNP rs7834157 (p=4.9x10
-8
), 
which maps 30kb upstream of C8orf4 (Figure 4.3b).   No evidence supporting this 
association was observed in women (p= 0.54) (Table 4.2). In women (Figure 4.1b), our 
top result, chromosome 14 SNP rs11628917 (p= 9.8x10
-8
), which maps ~1kb downstream 
of SERPINA1, narrowly missed genome-wide significance. No evidence for association 
was found for this same SNP in men (p= 0.54). 
In our combined-sex meta-analysis we identified significant evidence for 
association at chromosome 8 SNP rs341697 (p = 1.9x10
-8
), which maps ~80kb 
downstream of CSMD1 in a region not previously reported to be associated with Hcy 
levels.  Additionally, we identified two chromosome 11 polymorphisms (rs2289123, 
p=4.1x10
-9 
; rs317194 p=1.5x10
-8
 ) significantly associated with Hcy levels in the NOX4 
gene (Figure 1c). SNP rs2289123 maps <100bp upstream of the five prime untranslated 
region of NOX4 while rs317194 is an intronic SNP.4. Polymorphisms in NOX4 were 
previously reported to be associated with Hcy levels in a genome-wide analysis of EA 
women conducted by the Women’s Genome Health Study (Pare et al., 2009). 
Conditional Analysis  
 We performed a conditional analysis in the regions surrounding rs7834157, 
identified in our male cohorts, and rs341697, identified in our combined sex datasets (See 
Figures 4.3a and 4.3b).  For both regions, after conditioning on the top SNP in the region, 
the results for the remaining SNPs were attenuated (p> 0.005). 
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Comparison with other previously identified GWA loci 
 To compare our results to loci previously identified to be associated with Hcy in 
other GWA studies, we used log transformed Hcy values to maintain consistency with the 
models used in previous studies (Table 4.3).   
The well-studied non-synonymous polymorphism, rs1801133, in MTHFR at chromosome 
1 only reached nominal significance (p=0.028) in our dataset.  Evidence of sex specific 
effects was observed for non-synonymous polymorphism rs2274976 in the same locus 
region.  The effect was significant in women (p=0.038), but not significant and in the 
opposite direction in men (p=0.77).  CBS, which is involved in the transsulfuration 
pathway, was nominally associated (rs6586282, p=0.02) with Hcy in our sex-combined 
dataset.  Previously reported variants in NOX4 and MUT had the most significant 
associations (rs11018628 at NOX4, p= 1.1x10
-4
; rs4267943 at MUT, p= 9.6x10
-4
). We 
also observed evidence supporting the association between variant rs7422339 at the 
CPS1 gene and Hcy in women (p=0.033).  Consistent with earlier reports (Lange et al., 
2010; Pare et al., 2009), no evidence for such an association was observed in men 
(p=1.00).  
Association of CSMD1 rs341697 and IDO2 rs7834157 with other CVD-related traits 
 We tested the association between variants rs341697 at CSMD1 and rs7834157 at 
C8orf4(TC1) against LDL-C, HDL-C, BMI, and log C-reactive protein.  For both 
variants, we observed no associations with any of the CVD related traits even before or 
after adjustment for Hcy levels (data not shown).   
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Discussion 
 
 To our knowledge, this study conducted in approximately 3000 AAs from three 
community-based cohorts represents the first GWA scan for Hcy concentration in 
individuals of African descent.  We identified novel associations at 8p23 (rs341697) near 
CSMD1 in the sex-combined meta-analysis, and at 8p11 (rs7834157) near C8orf4(TC1) 
in the male-only meta-analysis. We also observed significant evidence for association at 
NOX4, a gene previously identified in a GWA analysis in EA women from the Women’s 
Genome Health Study (WGHS). 
 The cub and sushi multiple domains 1 (CSMD1) gene is a regulator of 
complement activity (Kraus et al., 2006) and has been implicated in several diseases, 
including hypertension and Kawasaki disease (Burgner et al., 2009; Hong et al., 2010).  
The Korean Association Resource (KARE) study performed a GWA analysis to identify 
variants associated with hypertension and blood pressure using approximately 8800 
subjects of Korean descent, followed by a replication analysis of the top SNPs in 
participants from the Health2 project (a Korean cohort of approximately 7800 
individuals). They identified a significant association at SNP rs995322 (p<0.001) near 
CSMD1 for hypertension (Hong et al., 2010).  A GWA analysis using an initial sample of 
Dutch individuals and a second sample of Australian trios to identify loci associated with 
Kawasaki Disease, an inflammatory vasculitis, which predominantly affects young 
children, observed association at SNP rs2912272 (p<0.002) at CSMD1 (Burgner et al., 
2009).   
 We observed significant evidence for association at rs7834157 near the gene  
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TC1(C8orf4), specific to males.  TC1 is well conserved among vertebrates suggesting an 
important biological role(Y. Kim et al., 2006).  TC1 has been implicated to have a 
potential role in inflammatory and immune regulation (J. Kim et al., 2009). TC1 is up-
regulated by the cytokine IL-1β, TNF-α, and cellular stresses in various cells (Y. Kim et 
al., 2006; Park et al., 2007).  TC1 also enhances the proliferation of dendritic cells, which 
are essential for B cell development (Y. Kim et al., 2006; Lee et al., 2005).  A study by 
Kim, et al. demonstrated that TC1 up-regulated the expression of IL-6, IL-1α, and 
ICAM1 in human aortic endothelial cells (HAEC).  Other adhesion molecules were also 
up-regulated (COX-2, CCL5, CXCL1, VCAM1, and E-selectin). The transfection of TC1 
in human umbilical vein endothelial cells (HUVECs) also up-regulated IL-6, IL-1α, and 
ICAM1 expression (J. Kim et al., 2009).  Knock down of TC1 by shTC1 in HAECs 
caused the expression of IL-6, IL-1α, and ICAM1 to be significantly down-regulated 
indicating the requirement of TC1 in endothelial inflammatory gene regulation.  In 
addition, the effect of I-kB-kinase (IKK), an NF-kB inhibitor, suppressed TC1 expression 
as well as expression of IL-1β regulated TC1 expression suggesting that TC1 expression 
is dependent on NF-kB activity.  NF-kB is activated under inflammatory conditions 
promoting the release of cytokines, chemokines, and intercellular adhesion molecules in 
endothelial cells (J. Kim et al., 2009).  TC1 also appears to have clinical relevance with 
respect to vascular regulation. TC1 downstream genes have been implicated in 
atherosclerosis (Hansson & Libby, 2006; Pober & Sessa, 2007; Rader & Daugherty, 
2008), and there is evidence of TC1 down-regulation by cardiovascular protective agents 
such as resveratrol and epigallocatechin-3-gallate (EGCG).  Resveratrol, found in red 
wine, and EGCG, a catechin in green tea, have been shown to have significant anti-
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inflammatory activities (Opie & Lecour, 2007; Potenza et al., 2007; Shenouda & Vita, 
2007).  Overall, previous literature suggests that this gene may have implications in 
CVD. 
The most associated SNP in the current study (rs2289123) is at NOX4, an enzyme 
in the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox) family, and 
was originally identified to be associated with Hcy in the WGHS. The Noxes are a family 
of enzymes that serve as a significant source of cellular reactive oxygen species (ROS).  
Low to moderate levels of ROS have been shown to contribute to important functions 
such as apoptosis, cell differentiation, adhesion, and senescence; however it has been 
demonstrated that elevated levels of ROS are associated with a variety of diseases 
including CVD (Lambeth, Kawahara, & Diebold, 2007).  The NOX4 gene is expressed in 
a wide array of tissue and cell types, which include cardiovascular tissues, hematopoetic 
stem cells, adipocytes, epithelial cells, and podocytes (Ikeda et al., 2011).  Unlike the 
other four Noxes that make up the Nox family, NOX4 does not require the binding of 
cytosolic proteins for ROS production but instead produces ROS constitutively (Martyn, 
Frederick, von Loehneysen, Dinauer, & Knaus, 2006). NOX4 expression in vascular cells 
was documented after its initial discovery in the kidneys (Geiszt, Kopp, Varnai, & Leto, 
2000).  Studies support that NOX4 is the most abundant Nox isoform in the vasculature.  
In blood vessels, NOX4 has a greater than 1000-fold copy number increase over NOX1 
and NOX2 and its expression has also been reported to be dominant in human and mouse 
cardiac myocytes (Byrne et al., 2003). Similar to ROS, elevated expression of NOX4 has 
been seen in patients with atherosclerosis, hypertension, and ischemic stroke (F. Chen, 
Haigh, Barman, & Fulton, 2012).  The amount of ROS contributed by NOX4 is regulated 
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at the transcriptional level (F. Chen et al., 2012) and the most significant SNP in this 
region (rs2289123) in our study is in moderate linkage disequilibrium (D’=0.7) with an 
NOX4 variant (rs2289124) in the 5’ untranslated region.  Data on this variant (rs2289124) 
comes from 1000 Genomes and we imputed SNPs from HapMap Phase 2 data, thus 
rs2289124 was not covered in our analysis.  However, this observation suggests that the 
combined polygenic effects of these variants may have a role in regulating NOX4 
expression in vascular cells and tissues.   
In human atherosclerosis, NOX4 expression is increased in intimal lesions of 
coronary arteries (Sorescu et al., 2002).  Decreased NOX4 expression has been seen in 
laminar flow, which has been shown to be protective against atherosclerosis and 
increased expression in oscillatory shear stress, which is proatherogenic.  Furthermore, a 
variety of oxidized lipids, such as ox-LDL can stimulate NOX4 expression in 
macrophages, which can then be scavenged by receptors to form atherosclerotic lesions.  
Because NOX4 can be influenced by multiple factors such as the severity of the lesion, 
the location of the blood vessel, and the presence of diseases such as inflammation and 
heart failure (Guzik et al., 2006), its role in atherogenesis still remains indeterminate.  
Similar to NOX4, the thiol metabolite of Hcy can combined with LDL-cholesterol to 
produce aggregates that are susceptible to uptake by macrophage (Kang, 1995); however 
the exact mechanisms underlying this gene’s influence on Hcy levels remains unclear. 
Interestingly, both rs341697 near CSMD1 and rs7834157 near TC1 lie within or 
near regions of structural variation specifically regions consisting of copy number 
variants (CNVs).  Data from previously reported CNVs tend to overstate the genomic  
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extent of actual variation while underestimating variation among individuals.  Therefore, 
these data could implicate that genomic alterations of these genes are frequent and do not 
necessarily predispose to disease risk (Shaikh et al., 2009); however, analysis of copy 
number variations across the human genome by Shaikh, et al. found these findings to be 
inconsistent.  Studies from the Database of Genetic Variation (DGV) collectively report 
49 CNVs (mean size: 347kb) within CSMD1 including seven segmental duplications 
spanning large stretches of the gene and 5 additional CNVs predicted to disrupt one or 
more CSMD1 exons (Conrad, Andrews, Carter, Hurles, & Pritchard, 2006; Perry et al., 
2008; Sharp et al., 2005).  In contrast, Shaikh, et al. identified 507 CNVs (mean size: 
7535bp) and only four were predicted to disrupt exonic sequences.  Moreover, this group 
did not identify any of the segmental duplications previously reported suggesting the 
possibility that these CNVs could be rare variants (Shaikh et al., 2009).  The CSMD1 
SNP observed in the current study (rs341697), lies within one of the CNV regions 
reported in the Shiakh study.  Four loss of function CNVs identified in a study by the 
1000 Genomes Project consortium were downstream of C8orf4(TC1) rs7834157 
(Genomes Project et al., 2010).  Thus, these variants could potentially be tagging the 
effects of nearby CNVs on Hcy concentration. 
Although variants in the MTHFR gene were the first to be implicated in the 
regulation of Hcy levels (Gudnason et al., 1998), their estimated effects in AAs in this 
study were notably smaller than seen in populations of European and Asian ancestry 
(Heijmans et al., 1999; Lange et al., 2010; Pare et al., 2009) which is consistent with what 
has been observed in other studies of AAs (Albert et al., 2009; Johnson et al., 2010).   
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While the association at CPS1 did not reach genome-wide significance, we 
observed nominally significant evidence of female-specific effects at rs7422339.  The 
association of CPS1 with Hcy was initially identified in women from the WGHS were the 
evidence for replication in that study came only from women in the follow-up sample, 
and the Cebu Longitudinal Health and Nutrition Survey (CLHNS) GWA in Filipinos also 
observed evidence for this locus only in women. The consistency of these findings 
suggest that variants in or near CPS1 may play a role in the regulation of homocysteine in 
women but have little or no effect in men.   
We also observed nominal evidence of female-specific effects at MTHFR , which 
is in contrast to evidence observed for male-specific effects observed in the CLHNS and 
several studies of populations of European ancestry (Pare et al., 2009; Tanaka et al., 
2009).  It is possible that the smaller effects of MTHFR may only be observed because 
MTHFR genotypes appear to be dependent on folate status, and generally African 
American women have lower levels with respect to EA men and women and AA men 
(Perry, et al). 
 Strengths of this study include that this represents the first GWA study for Hcy in 
AAs, and the relatively large sample size and high-density of common variants through 
genotype imputation allowed us to identify new genes influencing Hcy not previously 
identified in GWA studies of EAs and Filipinos. A limitation of this study is that we have 
not obtained confirmation of the two novel loci in an independent AA sample. These 
results, however, do provide new candidates for other AA samples with measured Hcy 
level.  As with any GWA study, SNPs identified may not be causally linked to variation  
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in Hcy concentrations, rather they may be in linkage disequilibrium with the causal 
variants. Even in the case that some of the variants identified may be functional, the 
functional mechanisms linking them to Hcy concentrations remain to be determined. 
Our findings provide additional insight regarding the genes that may be involved 
in the regulation of Hcy levels across and within populations.  While the NOX4 locus 
appears to have similar effects between AAs and EAs on Hcy concentration, the effects 
of MTHFR loci appear to be considerably smaller in AAs. In addition, given that the two 
novel loci identified in this study were not reported in the WGHS GWA of almost 14000 
EAs suggest that there may be genes with AA-specific effects on Hcy. Our findings 
emphasize the need to conduct GWA studies in non-European populations.   
 
Materials and Methods 
 
Study samples and Hcy measurement 
CARDIA 
CARDIA is a longitudinal study of the evolution of coronary heart disease risk, started in 
1985-86 in 5,115 AA and EA men and women, then aged 18-30 years. The CARDIA 
sample was recruited was recruited at random during 1985-86 primarily from 
geographically based populations in Birmingham AL, Chicago IL, and Minneapolis MN 
and, in Oakland, CA, from the membership of the Kaiser-Permanente Health Plan. 
Examinations after baseline were year 2 (1987-88, n=4624, 90% retention, year 5 (1990-
91, n=4352, 85% retention), year 7 (1992-93, n=4086, 80% retention), year 10 (1995-96, 
n=3950, 79% retention), year 15 (2000-2001, n=3672, 74% retention) and year 20 (2005-
06, n=3549, 72% retention). 
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Fasting serum samples that were collected in 2000 and stored frozen at −70 °C 
were used for Hcy measurement. tHcy was measured in serum by a fluorescence 
polarization immunoassay (IMx Homocysteine Assay, Axis Biochemicals ASA, Oslo, 
Norway) using the IMx Analyzer (Abbott Diagnostics, Abbott Park, IL). 
 
JHS 
The Jackson Heart Study (JHS) is a prospective population-based study to seek the 
causes of the high prevalence of common complex diseases among African Americans in 
the Jackson, Mississippi metropolitan area. During the baseline examination period 
(2000-2004) 5,301 self-identified African Americans were recruited from four sources, 
including (1) randomly sampled households from a commercial listing; (2) ARIC 
participants; (3) a structured volunteer sample that was designed to mirror the eligible 
population; and (4) a nested family cohort.  Unrelated participants were between 35 and 
84 years old, and members of the family cohort were ≥ 21 years old when consent for 
genetic testing was obtained and blood was drawn for DNA extraction.   
Fasting blood samples were collected and assayed for Hcy. Hcy was measured at 
the University of Minnesota, in conjunction with the University of Minnesota Medical 
Center, Fairview. Plasma Hcy was assayed by the fluorescence polarization immunoassay 
method, supplied by Abbott Diagnostics (Abbott Park, IL). 
 
MESA 
MESA is a cohort study of the characteristics of subclinical cardiovascular disease and 
the risk factors that predict progression to clinically overt cardiovascular disease or 
progression of subclinical disease. MESA researchers study a diverse, population-based 
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sample of 6,814 asymptomatic men and women aged 45-84: 2,622 white (39%), 1,893 
African-American (28%), 1,496 Hispanic (22%) and 803 (12%) of Asian (primarily 
Chinese) descent. Participants were recruited from six Field Centers across the United 
States (Winston-Salem, NC; St. Paul, MN; Chicago, IL; Los Angeles, CA; New York, 
NY; Baltimore, MD).   
Blood samples collected at baseline and were processed with the use of a 
standardized protocol and stored at 80 °C until analyzed.  Participants were asked to fast 
for 12 hours, avoid smoking on the morning of the exam, and avoid heavy 
Exercise 12 hours before the exam. Total plasma Hcy was measured with high-
performance liquid chromatography with fluorometric detection. The coefficient for 
variation for this assay was 3.8%. 
 
Genotyping/ Genotyping/Imputation 
 
Genome-wide genotyping on all cohorts was performed using the Affymetrix 6.0 
SNP Array (Affymetrix, Santa Clara, Calif). Genotype data was originally available on 
906,600 SNPs across the genome. SNPs were excluded if they had success rate less than 
90% of samples; subjects were removed if they had success rate less than 95% of SNPs. 
No SNPs were removed due to significant deviation from Hardy–Weinberg equilibrium 
(HWE) expectations because the AA population is an admixed population, which may 
result in departures from HWE expectations even under ideal conditions. After quality 
control, genotype data was available on ~800,000 autosomal SNPs in 3,817 AA subjects 
with Hcy measures. 
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Genotype imputation was performed using the software MACH (Y. Li et al., 
2010). HapMap phase 2 data sets (www.hapmap.org) were used for the reference panel 
(build 36 release 22) consisting of both YRI and CEU HapMap-phased haplotypes.  
Genotype imputation resulted in allelic-dosage data, representing the expected number of 
copies of the minor allele a subject carries, on approximately 2.2 million autosomal 
SNPs.  
 
Data analysis 
Hcy levels were highly skewed and simple transformations (e.g. natural log) did 
not remedy numerous outliers. Hence, we used inversed-normalized residuals, obtained 
from modeling Hcy on established non-genetic risk factors: age, body mass index (BMI) 
and current smoking status, as our outcome measure to meet linear model assumptions of 
normally distributed residuals and to minimize influence of extreme values when 
modeling Hcy on genotype. Residuals were calculated separately by cohort and by sex.  
We systematically performed linear regression models, implemented in PLINK (Purcell 
et al., 2007b),to test for associations between Hcy (using normalized residuals) and 
individual SNPs, with covariate adjustment for the first 10 principal components 
calculated using the program EIGENSTRAT (A.L. Price et al., 2006) to control for 
potential population substructure, assuming an additive genetic model. The association 
analyses were performed separately by cohort and by sex. After obtaining specific cohort 
results, we performed fixed-effect, inverse variance-weighted meta-analyses across 
cohorts using the METAL software (C.J. Willer et al., 2010) first separately by sex and 
then on the combined samples of men and women. Based on convention for imputed 
 91 
 
GWA studies, a p-
-8
 was used as the significance threshold 
for our results to maintain an overall experimental type I error rate of ~5%. Finally, 
conditional analyses, where association analyses are repeated with additional covariate 
adjustment for the top SNP in the region, were performed in selected regions that 
demonstrated evidence for association to assess whether there was any evidence for 
multiple independent signals in the regions of interest. 
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Table 4.1. Descriptive table of participants by study 
 
 CARDIA JHS MESA 
 Men Women Men Women Men Women 
N 167 284 796 1220 623 727 
Current Smoker, % 31.4 27.8 19.5 12.2 20.0 15.8 
Age, y 24.70±3.75 24.60±3.87 49.49±11.84 50.26,12.05 61.78±9.88 61.57±9.82 
BMI, kg/m
2 24.63±3.77 26.08±5.80 30.2±6.42 33.49±8.25 28.79±4.51 31.28±6.28 
Homocysteine, 
umol/L 
 
10.38±3.08 8.33±2.61 9.77±3.03 8.67±4.23 10.38±4.91 8.92±3.21 
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Table 4.2. Evidence of most significant associations with Hcy values for stratified and combined meta-analysis  
      Both Men Women 
Chr GENE SNP Location Effect 
Allele 
MAF Beta(SE) Pvalue Beta(SE) Pvalue Beta(SE) Pvalue 
11 NOX4 rs2289123 88864366 T 0.29 0.16(0.028) 4.09x10
-9 
0.20(0.043) 3.47x10
-6 
0.14(0.037) 1.59x10
-4 
11 NOX4 rs317194 88727291 T 0.43 -0.16(0.029) 1.45x10
-8 
-0.16(0.045) 1.78x10
-4 
-0.16(0.037) 2.09x10
-5 
8 CSMD1 rs341697 2729496 T 0.31 -0.15(0.028) 
 
1.90x10
-8 
-0.14(0.044) 9.58x10
-4 
-0.16(0.036) 5.10x10
-6 
8 C8orf4 
(TC1) 
rs7834157 40093249 C 0.17 0.12(0.032) 7.95x10
-5 
0.27(0.050) 4.88x10
-8 
0.03(0.042) 0.539 
14 SERPINA1 rs11628917 93913472 T 0.05 -0.29(0.063) 3.05x10
-6 
-0.06(0.108) 0.544 -0.42(0.078) 9.77x10
-8 
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Table 4.3. Evidence of association with log-Hcy values at previously reported GWA loci  
    Original Study Current Study 
       Both Men Women 
Author Chr GENE SNP MAF Beta MAF Beta(SE) Pvalue Beta(SE) Pvalue Beta(SE) Pvalue 
Lange, 
LA, et al. 
(W) 
1 MTHFR rs1801133 0.22 0.083 0.12 0.028(0.01) 0.028 0.023(0.02) 0.239 0.032(0.02) 0.060 
Tanaka, 
et al. 
(M and 
W) 
1 MTHFR rs1801133 0.47 1.31 0.12       
Pare, G, 
et al. 
(W) 
1 MTHFR rs2274976 0.05 -0.062 0.05 -0.026(0.02) 0.137 0.009(0.03) 0.768 -0.046(0.02) 0.038 
Lange, 
LA, et al. 
(W) 
2 CPS1 rs7422339 0.24 0.076 0.32 0.013(0.008) 0.100 -0.000(0.01) 0.998 0.022(0.01) 0.033 
Pare, G, 
et al. 
(W) 
2 CPS1 rs7422339 0.31 0.027 0.32       
Pare, G, 
et al. 
(W) 
11 NOX4 rs11018628
 
0.07 -0.05 0.14 0.036(0.009) 1.1x10
-4 
0.034(0.01) 0.021 0.038(0.01) 0.002 
Pare, G, 
et al. 
(W) 
6 MUT rs4267943 0.36 0.024 0.39 0.022(0.007) 9.6x10
-4 
0.014(0.01) 0.169 0.028(0.009) 0.001 
Pare, G, 
et al. 
(W) 
16 DPEP1 rs459920 0.44 0.024 0.22 0.012(0.009) 0.214 0.002(0.01) 0.811 0.022(0.01) 0.100 
Pare, G, 
et al. 
(W) 
21 CBS rs6586282 0.18 -0.030 0.25 -0.021(0.009) 0.023 -0.02(0.01) 0.071 -0.018(0.01) 0.160 
*for comparison purposes these betas are based on log Hcy 
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Figure 4.1a. GWAS results for inverse normal Hcy levels in 1, 586 African American men. Loci described in the text are annotated 
with gene symbols 
. 
 
 
 
TC1(C8orf4) 
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Figure 4.1b. GWAS results for inverse normal Hcy levels in 2,231 African American women.  Loci described in the text are 
annotated with gene symbols 
 
 
 
 
SERPINA1 
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Figure 4.1c. GWAS results for inverse normal Hcy levels in 3,817 African American men and women. Loci described in the text are 
annotated with gene symbols. 
 
 
 
 
NOX4 
CSMD1 
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Figure 4.2a. Quantile-quantile plot of SNP association with inverse-normalized Hcy 
values.in African American males.  
Red circles indicate all SNPs.  A solid black line indicates the uniform expectations and the gray 
dashed lines indicate the 95% prediction interval 
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Figure 4.2b. Quantile-quantile plot of SNP association with inverse-normalized Hcy 
values.in African American females.  
Red circles indicate all SNPs.  A solid black line indicates the uniform expectations and the gray 
dashed lines indicate the 95% prediction interval
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Figure 4.2c. Quantile-quantile plot of SNP association with inverse-normalized Hcy 
values.in African American males and females.  
Red circles indicate all SNPs.  A solid black line indicates the uniform expectations and the gray 
dashed lines indicate the 95% prediction interval 
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Figure 4.3a. Locus zoom plot of the CSMD1 gene region (8p11) in African American men and women.   
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Figure 4.3b. Locus zoom plot of the TC1(C8orf4) gene region (8p23) in African American men 
 
 
  
 
 
 
 
 
CHAPTER 5 
CONCLUSIONS 
 
The aims of this dissertation were to identify loci that influence CRP and Hcy 
levels and assess whether two GST gene variants modify the effects of cigarette smoking 
on CRP.  The first paper identified common and uncommon variants associated with CRP 
in EAs and AAs using a dense SNP array designed specifically to capture the variation of 
candidate genes for CVD pathways (IBC chip).  The second paper focused on testing for 
interactions between polymorphisms in two genes involved in cellular detoxification, 
GSTM1 and GSTT1, and cigarette smoking on CRP level in EAs and AAs.  The third 
paper was a genome-wide association scan conducted on AAs from three population-
based cohorts to identify loci associated with Hcy levels. 
Major Findings 
 
The results of the first paper support a novel association between an uncommon CD36 
variant and CRP in AAs.  It also provides additional confirmatory evidence for several 
previously identified genes associated with CRP in both EAs and AAs.  The non-
synonymous SNP rs3211938 identified to be associated with CRP is specific to 
populations of African ancestry, and the uncommon variant was associated with lower 
CRP levels.  This is in line with previous literature that supports the association between 
this SNP and elevated HDL levels conferring a cardio-protective effect in AAs. 
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 The results from the second paper provide support that GSTT1 genotype modifies 
the association between cigarette smoking and CRP in EAs, with log-pack-years of 
smoking being more positively associated with CRP level in individuals who  
are homozygous for the more common allele as compared to the other two genotypes.  
Thus, the data support that the uncommon variant for SNP rs405597 is protective of the 
effects of amount of cigarette smoking, as assessed by log-pack-years.  While this 
analysis utilized polymorphisms available on the IBC chip, it is likely that a functional 
deletion, tagged by the rs405597 SNP is responsible for the effect modification.   
 Lastly, we identified two putative novel associations in a genome-wide 
association scan for Hcy: at 8p23 near CSDM1 and a male-specific locus at 8p11 near 
TC1(C8orf4).  We also replicated evidence for the NOX4 locus, which was identified in 
EA women from the Women’s Genome Health Study, and sex-specific effects at CPS1 in 
AA women, which was previously observed in EAs and Filipinos. Interestingly, there 
was little evidence of effect for two polymorphisms in the well-studied MTHFR gene 
established as influencing Hcy in populations of European and Asian ancestry. The 
results from this study underscore the value of conducting genome-wide association 
studies in non-European populations. 
While genome-wide association and candidate gene studies have been successful 
in identifying multiple loci associated with CVD, most of these studies have been focused 
on populations of European descent.  It has been demonstrated that the use of non-
European samples can improve the power to detect susceptibility loci (N.A. Rosenberg et 
al., 2010).  Pulit et al. showed that minor allele frequency differences across populations 
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can lead to dramatically different levels of statistical power to detect associations (Pulit et 
al., 2010).  Because of these differences in allele frequencies, the incorporation of  
multiple ethnic samples can help elucidate the range of genetic loci influencing 
phenotypes of interest. Our studies provide strong empirical evidence supporting the 
value of using other populations to identify loci associated with CVD traits. Notably, we 
identified an uncommon variant, near private to African Americans, in CD36 that is 
associated with CRP, a gene that has not been previously implicated to be important to 
CRP. We also identified two novel loci for Hcy in the first GWA study of Hcy in AAs, 
including one near the strong candidate gene CSDM1. 
Future Directions/Studies 
 
Chapters 1 and 3 described large-scale association studies used to identify loci associated 
with CRP and Hcy, respectively, while paper 2 described a targeted candidate gene study 
designed to assess whether the effect of exposure to cigarette smoke on CRP is modified 
by variants in genes previously reported to interact with smoking exposure.   
For chapter 1, future replications studies using similar populations would be 
desirable to corroborate our observed finding of an association between CRP and a CD36 
variant rs3211938. While we have confirmed the finding in our own replication sample, 
future studies could provide refined and more precise effect-size estimates. This variant is 
specific to populations of African descent; previous literature has identified an 
association between rs3211938 and HDL levels in African Americans, suggesting that 
this variant has a protective effect in this population (Love-Gregory et al., 2011).  While 
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evidence for association in our own study remained after covariate adjustment for HDL 
levels, we only had one HDL measurement available to us that was measured at the same  
time or prior to the CRP measurement for most samples.  Larger sample sizes that include 
repeated measures of CRP and HDL would be valuable in further understanding the 
relationship between this variant, HDL and CRP. Our findings certainly suggest that this 
and other CD36 variants warrant further investigation regarding their predictive value for 
clinical endpoints and utility as a diagnostic tool to help clinicians determine CVD risk in 
AAs. 
Chapter 2 describes a candidate gene study used to assess whether GSTM1 and 
GSTT1 genotypes modify the effects of smoking exposure on CRP.  Larger samples and 
more precise smoking indices will be necessary to confirm our identified interaction 
between cigarette smoking and GSTT1 rs405597 and CRP.  We used pack-years as a 
measure of smoking index in our analysis.  This measure has been widely used in many 
epidemiological studies because it combines measures of smoking magnitude and 
intensity.  However, we understand that this index lacks precision because it makes the 
assumption that the dose of smoking one cigarette per day for 10 years is equivalent to 
smoking 10 cigarettes per day for one year (Doll & Peto, 1978). Second, size of the pack 
can also differ from brand to brand but there is a general agreement that there are 20 
cigarettes in one pack.   Ideally, multiple factors should be taken into account when 
measuring smoking status, such as levels of carbon monoxide exhalation, types of  
cigarettes smoked (filter and non-filter), age and start of passive smoking (environmental 
tobacco exposure) (Indrayan & Sarmukaddam, 2001).  Because accurately quantifying all 
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these measures presents itself with tremendous difficulty, it is more important to identify 
the most optimal measure for the outcome being investigated.   
Additionally, this study also alludes to the need to characterize more variants 
within the GST classes so that we can more fully capture the variation in these genes, 
including functionality important less common variants.  Much of the literature is focused 
on GST deletion regions and it would be useful to more precisely understand the 
relationship between our common variants and these deletions. Further analysis of LD 
patterns and haplotypes in these genes across multiple populations may also uncover 
novel functionally critical variants.   
For chapter 3, replication studies are necessary to confirm evidence of association 
between Hcy and genes CSMD1 and TC1(C8orf4) identified in our genome-wide analysis 
of AAs and whether these findings can be generalized to other populations.  Further, the 
sex-specific result of TC1 being only seen in AA males needs to be validated, and if true, 
better understood. It would be a valuable exercise to fine map these regions surrounding 
these loci using haplotype analyses and next-generation sequencing data to identify any 
uncommon variants that our leading SNPs may be tagging.  In addition, because we 
observed that both rs7834157 (TC1(C8orf4)) and rs341697 (CSMD1) are near regions of 
copy number variation (CNVs), we will utilize available copy number variation data to 
determine whether these SNPs are tagging the effects of these known CNVs  Both genes 
have a biological role in relation to CVD.  CSMD1 is located in a region that contains a  
large amount of immune-related genes and is hypervariable in humans (Burgner et al., 
2009). CSDM1 has been implicated in hypertension in a Korean cohort (Hong et al., 
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2010) and Kawasaki disease, an inflammatory vasculitis, which predominantly affects 
young children, in a Dutch cohort (Burgner et al., 2009).   
TC1(C8orf4) has been implicated in diverse biological regulations.  There is evidence of 
TC1 down-regulation by cardiovascular protective agents such as resveratrol and 
epigallocatechin-3-gallate (EGCG) suggestive of its clinical relevance in vascular 
regulation (Opie & Lecour, 2007; Potenza et al., 2007; Shenouda & Vita, 2007).  
Pharmacological inhibition of NF-κB caused a downregulation of TC1 expression in 
human aortic endothelial cells (HAECs) supporting evidence that TC1 expression is 
dependent on NF-κB activity (J. Kim et al., 2009).  However, further investigation is 
needed to determine the roles of TC1 and CSMD1 in the regulation of Hcy levels. 
Public Health Implications 
 
CVD is the leading cause of death in the US, making it a critical public health concern.  
Currently, 1 in 3 Americans have some form of heart disease, including high blood 
pressure, coronary heart disease, heart failure, stroke and other conditions. By 2030, 
approximately 116 million people in the US (40.5 percent) will have some form of CVD 
(Heidenreich et al., 2011).  In 2010, the total cost of CVDs in the US was estimated to be 
$444 billion, and productivity losses due to heart disease, which include days missed 
from work tasks due to illness or potential lost earnings due to premature death, were 
estimated to be $172 billion (Kuklina, Tong, George, & Bansil, 2012).   
New projections from the American Heart Association propose that by 2030, the cost of 
medical care for CVD-related morbidities will escalate to $818 billion and productively 
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losses will reach $276 billion (Heidenreich et al., 2011).  Although numerous advances 
have been made in risk assessment, disease prognosis, and the development of more 
effective therapeutics, there are still critical areas of CVD etiology that require additional 
insight to continue making progress in reducing the disease burden, including identifying 
factors that may underlie differences in risk across ethnic groups.  Multi-ethnic genetics 
studies can, in part, address this area of need.   
A better understanding of the genetic factors influencing CVD biomarkers across 
ethnicities, as well as identifying genes that modify the effects of established risk factors 
on these biomarkers, will provide important insight regarding the pathophysiology of 
CVD, provide health-care providers with better methods of identifying individuals at 
increased risk, as well as allowing for the potential of future personalization of 
interventions and treatment. 
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APPENDIX I 
 
Supplemental Methods: 
Participating cohorts 
Atherosclerosis Risk in Communities Study (ARIC) 
ARIC is a longitudinal cohort study of atherosclerosis and its clinical sequelae.  From 
1987 to 1989, a population-based sample of 15,792 men and women aged 45 to 64 years 
were recruited from 4 US communities (Forsyth County NC, Jackson MS, suburban 
Minneapolis MN, and Washington County MD). CRP was assessed using the 
immunoturbidimetric CRP-Latex (II) high-sensitivity assay from Denka Seiken (Tokyo, 
Japan).  This assay, which has been validated against the Dade Behring method 
(Deerfield, Ill), was performed according to the manufacturer’s protocol and using a BN2 
analyzer (Dade Behring (Deerfield, Il).  To assess repeatability of measurements, 421 
blinded replicates were measured on different dates. The reliability coefficient was 0.99 
 
Coronary Artery Risk Development in Young Adults (CARDIA)  
CARDIA is a longitudinal study of the evolution of coronary heart disease risk, started in 
1985-86 in 5,115 AA and EA men and women, then aged 18-30 years. The CARDIA 
sample was recruited was recruited at random during 1985-86 primarily from 
geographically based populations in Birmingham AL, Chicago IL, and Minneapolis MN 
and, in Oakland, CA, from the membership of the Kaiser-Permanente Health Plan. 
Examinations after baseline were year 2 (1987-88, n=4624, 90% retention, year 5 (1990-
91, n=4352, 85% retention), year 7 (1992-93, n=4086, 80% retention), year 10 (1995-96, 
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n=3950, 79% retention), year 15 (2000-2001, n=3672, 74% retention) and year 20 (2005-
06, n=3549, 72% retention). 
At the Year 15 and 20 examinations, bloods for measurement of CRP were collected in 2-
mL blue top (citrated) vacutainer tubes and centrifuged at 4°C for approximately 20 
minutes. Citrated plasma was promptly separated from cells, transferred to a cryovial, 
and frozen at −70°C. Frozen samples were shipped to the University of Vermont where 
CRP was measured using high-sensitivity nephelometry-based methods (BNII 
nephelometer, Dade Behring). The assay range was 0.175–1100 mg/L, (intrassay CVs, 
2.3–4.4%; inter-assay CVs, 2.1–5.7%). Measurement of CRP was blind to depressive 
symptom scores. 
 
Cleveland Family Study (CFS) 
The Cleveland Family Study (CFS) comprises 2,534 individuals (46% AA) from 352 
families examined every 4 years over a 16 year period (1990-2006). The study was begun 
with the initial aim to quantify the familial aggregation of sleep apnea. Index probands 
(n=275) were recruited from 3 area sleep centers if they had a confirmed diagnosis of 
sleep apnea and at least 2 first-degree relatives available to be studied. In the first 5 study 
years, neighborhood control probands (n=87) with ≥ 2 living relatives available were also 
recruited. All available first-degree relatives and spouses of the case and control probands 
were recruited. Blood was sampled and DNA isolated for subjects seen in the last 2 exam 
cycles (n=1447). The 4th exam included 736 subjects (60% African American), with 
oversampling subjects who had had a microsatellite genome scan. CRP was measured 
during the 4
th
 exam. 
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Cardiovascular Health Study (CHS) 
The CHS is a population-based, observational study of risk factors for clinical and 
subclinical cardiovascular diseases. The study recruited participants 65 years and older 
from 4 US communities (Forsyth County, North Carolina; Sacramento County, 
California; Washington County, Maryland; and Pittsburgh, Pennsylvania) in 2 phases: 
5201 participants from 1989 to 1990, and 687 (primarily AA participants) from 1992 to 
1993. Blood was drawn in all participants and samples were promptly centrifuged at 
3000g for 10 minutes at 4°C.  Aliquots of plasma were stored in a central laboratory at -
70°C.  CRP was measured in all stored baseline plasma samples by a high-sensitivity 
immunoassay, with an inter-assay coefficient of variation of 6.25%. 
 
Framingham Heart Study (FHS) 
The FHS started in 1948 with 5209 randomly ascertained participants from Framingham, 
MA, who had undergone biannual examinations to investigate cardiovascular disease and 
its risk factors. In 1971, the offspring cohort (comprised of 5124 children of the original 
cohort and the children’s spouses) and in 2002, the third generation (consisting of 4095 
children of the offspring cohort), were recruited. FHS participants in this study are of 
European ancestry. CRP was measured in fasting serum samples using a high-sensitivity 
assay (Dade Behring BN100).  The minimum detectable does of this assay is 0.16mg/L, 
with a standard curve range of 0.16-1000mg/L.  The intra-assay coefficient of variation 
was 3.2%, while the inter-assay coefficient of variation was 5.3%.  The final population 
for this analysis included individuals (Offspring n=3,582, Third Generation n=3,047). 
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Jackson Heart Study (JHS) 
The Jackson Heart Study (JHS) is a prospective population-based study to seek the 
causes of the high prevalence of common complex diseases among African Americans in 
the Jackson, Mississippi metropolitan area. During the baseline examination period 
(2000-2004) 5,301 self-identified African Americans were recruited from four sources, 
including (1) randomly sampled households from a commercial listing; (2) ARIC 
participants; (3) a structured volunteer sample that was designed to mirror the eligible 
population; and (4) a nested family cohort.  Unrelated participants were between 35 and 
84 years old, and members of the family cohort were ≥ 21 years old when consent for 
genetic testing was obtained and blood was drawn for DNA extraction.  CRP was 
measured using the immunoturbidimetric CRP-Latex assay from Kamiya Biomedical 
Company following manufacturer's high-sensitivity protocol. The inter-assay coefficients 
of variation on control samples repeated in each assay were 4.5% and 4.4% at CRP 
concentrations of 0.45 mg/L and 1.56 mg/L respectively. The reliability coefficient for 
masked quality control replicates was 0.95 for the CRP assay. 
 
Multi-ethnic Study of Atherosclerosis 
MESA is a cohort study of the characteristics of subclinical cardiovascular disease and 
the risk factors that predict progression to clinically overt cardiovascular disease or 
progression of subclinical disease. MESA researchers study a diverse, population-based 
sample of 6,814 asymptomatic men and women aged 45-84: 2,622 white (39%), 1,893 
African-American (28%), 1,496 Hispanic (22%) and 803 (12%) of Asian (primarily 
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Chinese) descent. Participants were recruited from six Field Centers across the United 
States (Winston-Salem, NC; St. Paul, MN; Chicago, IL; Los Angeles, CA; New York, 
NY; Baltimore, MD).  High sensitivity CRP was determined by BNII nephelometer (N 
High Sensitivity CRP, Dade Behring Inc, Deerfield, IL). The lower limit of detection was 
0.17 mg/L.  
 
Women’s Health Initiative (WHI) 
WHI is one of the largest (n=161,808) studies of women's health ever undertaken in the 
U.S. There are two major components of WHI: (1) a Clinical Trial (CT) that enrolled and 
randomized 68,132 women ages 50 – 79 into at least one of three placebo-control clinical 
trials (hormone therapy, dietary modification, and calcium/vitamin D); and (2) an 
Observational Study (OS) that enrolled 93,676 women of the same age range into a 
parallel prospective cohort study. A diverse population including 26,045 (17%) women 
from minority groups were recruited from 1993-1998 at 40 clinical centers across the 
U.S. The design has been published. For the CT and OS participants enrolled in WHI and 
who had consented to genetic research, DNA was extracted by the Specimen Processing 
Laboratory at the Fred Hutchinson Cancer Research Center (FHCRC) using specimens 
that were collected at the time of enrollment in to the study (between 1993 and 1998).  
According to a standardized protocol, fasting blood specimens
 
were collected 
from each participant at baseline and processed
 
locally into separate aliquots containing 
serum, plasma, and
 
buffy coat. The aliquots were frozen and then shipped to a central
 
repository, where they were kept for long-term storage at –70°C. All biochemical assays 
were carried out by laboratory staff
 
blinded to case/control status (in Dr Rifai's 
 115 
 
laboratory). Blood
 
samples from cases and their matched controls were handled 
identically,
 
shipped in the same batch, and assayed in random order in the
 
same analytical 
run to reduce systematic bias and interassay
 
variation.  High-sensitivity C-reactive protein 
(hsCRP) was measured
 
on a chemistry analyzer (Hitachi 911; Roche Diagnostics, 
Indianapolis,
 
Indiana) using an immunoturbidimetric assay with reagents and
 
calibrators 
(Denka Seiken Co Ltd, Niigata, Japan). The coefficients
 
of variation were 1.61% for 
hsCRP. 
 
KORA 
KORA stands for Cooperative Health Research in the Augsburg Region ("Kooperative 
Gesundheitsforschung in der Region Augsburg").  CRP was measured in EDTA plasma 
by a high sensitivity in-house immunoradiometric assay (IRMA) in MONICA/KORA S3, 
using a five-point calibration with WHO International Reference Standard 85/506.  The 
assay range was 0.05-10mg/L.  Sample with concentrations >10mg/L were remeasured at 
higher dilutions. CRP concentrations were determined in triplicate, and the mean was 
used for analysis. The inter-assay CV for CRP over all ranges was 12%. 
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